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ABSTRACT OF THE DISSERTATION

Maintenance of CD4 and CD8
T Cell Response to Persistent Antigens
by
Yu Xia

Doctor of Philosophy in Biology and Biomedical Sciences
Immunology
Washington University in St. Louis, 2022
Professor Takeshi Egawa, Chair
In response to transient antigen presence in the context of acute infections or
vaccinations, antigen-specific naïve T cells clonally expand and differentiate. Most of the
expanded cells undergo terminally differentiation and die following antigen clearance to reestablish immune homeostasis. In contrast, when the pathogen persists, such as in the context of
chronic viral infections or anti-tumor immunity, while T cells undergo alternative differentiation
known as exhaustion due to their reduced functionality, T cells still contribute to pathogen
control and its response is sustained for longer duration due to unknown mechanisms. The goal
of my thesis work is to understand how protective T cell response is sustained at the cellular
levels and molecular levels for CD8 T cells and CD4 T cells in the presence of persistent
antigens. The main model used is the mouse chronic lymphocytic choriomeningitis virus
(LCMV-clone 13, c13) infection model, which causes viremia that lasts 3-4 months in
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immunocompetent mice and is subsequently resolved in a manner dependent on CD4 and CD8 T
cells.
In the analyses of CD8 T cell responses, I identified previously undescribed populations
of CD8 T cells that express the chemokine receptor CX3CR1 and further segregated into two
populations based on expression of the inhibitory receptor TIM3. CX3CR1+ TIM3+ cells, despite
the expression of inhibitory receptors, maintain proliferative states and express effector
molecules, thus contributing to antiviral responses to the persisting virus. In contrast, the TIM3–
CX3CR1+ CD8 T cells are quiescent, require the transcription factor T-bet, express low but
significant levels of TCF-1, and act as immediate precursors for the TIM3+ CX3CR1+ CD8 T
cells. These findings reveal hierarchical differentiation of exhausted CD8 T cells which transit
from the previously reported TCF-1hi stem-like progenitor (TPEX) state, to T-bethi intermediate
progenitor (TIM3+ CX3CR1+) state, to activated effector (TIM3+ CX3CR1+) state, which
mediates sustained CD8 T cell immunity to persistent viral infection.
In studies of CD4 T cell responses, I demonstrated that in addition to the differentiated
TH1 and follicular helper (Tfh) cells, activated CD4 T cells also differentiate into memory-like
cells in a BCL6-dependent manner. While the initial TH1 cells and Tfh cells are generated
through independent developmental pathways directly from naïve T cells, as infection persists,
TH1 cells and Tfh cells are both generated from this newly identified memory-like cells, which
is required to maintain both TH1 and Tfh responses for prolonged duration. In response to
tumors, an analogous CD4 T cell population develops in draining lymph nodes. These findings
reveal the heterogeneity and plasticity of CD4 T cells upon encountering persistent antigen and
highlights their population dynamics through a stable and bipotent intermediate state.
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Chapter 1: Introduction
1.1 Overview of the immune system
Organisms big and small have evolved ways to defend against invading pathogens. Even
prokaryotes have evolved molecular mechanisms that help them fend off invaders such as
phages. An example is CRISPR-Cas, a microbial defensive strategy used by bacteria and archaea
that uses RNA-guided nucleases to cleave foreign genetic elements1. Organisms that are more
complicated have evolved more sophisticated tools and strategies to protect themselves from a
whole array of pathogens from virus to bacteria to fungi, and the system that enables the
multifaceted protective response is termed the immune system, which consists of a variety of
effector cells and molecules.
The first line of defense against pathogens are not made of immune cells, but rather
physical and chemical barriers that keep most pathogenic microbes from entering into the body
and becoming pathogenic. The skin, mucosa and epithelium provide a physical barrier that ward
off many pathogens, and their barrier function is made obvious in patients with damaged skin or
mucosa tissue, who are under high risk for infections. In addition, the skin and mucosa secret
broad-spectrum antimicrobial proteins that act as natural antibiotics. This physical and chemical
barrier is often enough to protect the host against pathogens. Sometimes, however, the pathogen
can successfully bypass these barriers and gain entrance into the organism, which alerts and
activates the immune system.
The immune system consists of the innate immune system and the adaptive immune
system, with the former acting faster by recognizing general pathogen- or damage-related
patterns and the latter mounted slower with more specificity and immune memory formation.
1

Both innate and adaptive immune responses depend on the white blood cells, or leukocytes,
some of which circulate in the bloodstream or patrol in a specialized immune structure called the
lymphatic system, and some of which are stationed within specific tissues and organs.
Leukocytes are mostly derived from the hematopoietic system stem cells (HSCs) in the bone
marrow, and can be segregated into two categories, namely, the myeloid lineage and the
lymphoid lineage. Cells from the myeloid lineage comprise a majority of the innate immune
system although some players are derived from the lymphoid lineage, and the rest of the cells
from the lymphoid lineage make up the adaptive immune system.
The innate immunity functions as the second line of defense against pathogens. Upon
barrier breach, complement gets quickly involved which, together with antibodies, can directly
lyse the invading microbe2. Macrophages and dendritic cells (DCs) act as the first cell
responders, which is made possible by their location in the barrier tissues and their expression of
specialized microbial-detecting sensors called pattern-recognition receptors (PRRs), which allow
them to recognize molecular structures shared among a variety of pathogens called pathogenassociated molecular patterns (PAMPs)3. One example of PAMPs is lipopolysaccharide (LPS),
which is commonly seen in Gram negative bacteria. Following PAMP recognition, macrophages
secrete cytokines and chemokines that leads to the recruitment of more innate immune cells,
such as granulocytes (include neutrophils, eosinophils and basophils), innate lymphoid cells
(ILCs), and natural killer cells. Many of these cells are also equipped with sensors for danger
signals, such as PAMPs and, in the case of NK cells, decrease of self-antigen presentation which
is a common feature of many virally infected cells4. These recruited innate immune cells carry
various effector functions, such as cell killing or production of cytokines with direct
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antimicrobial activity. Together, the innate immune cells get quickly activated and protect the
host from the majority of microbial invasion.
Sometimes, the innate immune system is insufficient to clear the pathogen, and the
adaptive immune response is required. The immune cells that mediate the adaptive immunity are
B lymphocytes and T lymphocytes, which carry unique B cell receptors or T cell receptors (BCR
and TCR) that allow them to recognize unique molecules expressed by a particular pathogen
with high specificity. The BCRs and TCRs are results of gene segment rearrangement called
V(D)J recombination5, which yields an astoundingly high number of BCRs and TCRs. Upon
BCR or TCR activation, the naïve B cells or T cells clonally expand and differentiate into cells
with various effector functions.
Many B cells become antibody-secreting cells, and the antibody is a secreted form of the
BCR that binds antigens in the extracellular department for marking of infected cells for
destruction or neutralization of the pathogen to prevent its entry into tissues. The breadth of BCR
goes beyond that produced by V(D)J recombination alone, as many activated B cells are selected
to go through more genetic mutations carried out in a programmed process called somatic
hypermutation in an effort to generate BCRs of higher affinity6.T cells, on the other hand, only
carry membrane-bound TCRs that recognize peptides presented by major histocompatibility
complex (MHC) or MHC-like molecules. Depending on the types of TCR chains, T cells can be
categorized as alpha beta T cells or gamma delta T cells. Alpha beta T cells are found across the
tissues and can be either CD4 or CD8 T cells, with CD4 and CD8 being the co-receptor for the
TCR; gamma delta T cells are found primarily in epithelium and mucosa, and lack expression of
the CD4 or CD8 co-receptors. CD4 T cells secrete cytokines and provide contact-dependent help
to coordinate the overall immune response in addition to exert direct antimicrobial functions7.
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CD8 T cells differentiate into cells with cytotoxic functions, thus also called cytotoxic T
lymphocytes (CTLs), that lyse cells carrying intracellular pathogens8.
With the production of high-affinity antibodies and clonal expansion of antigen-specific
T cells that carry various effector functions, the adaptive immunity is able to control the
pathogen to achieve partial control or total eradication.

1.2 T cell activation and antigen recognition
After development in the thymus, naive T cells reach the bloodstream and traffic to the T
cell zone of secondary lymphoid organs (SLOs) including the spleen and lymph nodes. Naive T
cells continuously circulate between blood and those SLOs in search for its cognate antigen9.
Upon antigen recognition via peptide: MHC (p: MHC) presentation by DCs under the
appropriate context, which occurs in the SLOs, the naive T cells get activated (called priming)
and undergo clonal expansion and differentiation to generate effector T cells.
The activation of T cells of DCs is a tightly regulated process, which requires the
presence of 3 different signals: binding of the cognate p:MHC to the TCR (Signal 1); costimulation provided by DCs (Signal 2)10, which can only occur after DCs have matured due to
inflammatory input and is a sign of uncontrolled pathogen invasion; and cytokines provided by
DCs as well as other innate and adaptive cells types (Signal 3)11 which carries instructive
information on what kind of immune response is appropriate to mount. T cells that have received
only signal 1 will remain anergic. In this way, the adaptive immune response is tailored to the
needs of the host when and only when there is pathogen invasion.
CD4 T cells and CD8 T cells differ in one important regard, the type of MHC molecule
that they can recognize at priming and during effector phase. CD4 T cells recognize peptides
4

presented on MHCII and CD8 T cells recognize peptides presented on MHCI. The two kinds of
MHC molecules differ in the source of peptides loaded onto them and their expression pattern
among different types of cells. The source of peptides will dictate what kind of antigens CD8 or
CD4 T cells can see, and the expression patterns of MHC I or MHC II will dictate what kind of
cells CD8 or CD4 T cells can recognize12.
MHC I and MHC II have different loading mechanisms for peptides. Peptides loaded
onto MHC I are products of proteasome-mediated degradation, which means that MHC I allows
presentation of cytosolic proteins, such as mutated proteins from a tumor cells or viral proteins
for an infected cell, to cytotoxic CD8 T cells that have been primed by DCs, and be killed
subsequently. MHCII, on the other hand, is used to load epitopes derived from proteins in
membrane-enclosed vesicles, which might contain intracellular pathogens such as mycobacteria
and antigens taken from the extracellular space such as dead cells. The loading of intravesicular
and extracellular antigens onto MHCII allows CD4 T cells to recognize a wide range of
pathogens that are not accessible to the cytosol. This way, CD4 and CD8 T cells have a division
of labor in terms of the source of antigens they recognize.
MHC I and MHC II also have different expression patterns among different cell types.
Although only DCs can prime CD4 and CD8 T cells, more cell types can express MHC II and/or
MHC I to present peptides and engage the effector function of CD4 T and CD8 T cells post
priming. MHC II is expressed only on professional antigen presenting cells (APCs), including
DCs, macrophages, and B cells, which means that only these cells can engage primed CD4 T
cells to get help. This design allows a tight regulation of the delivery of CD4 T cell help, which
is desirable considering the multifaceted role CD4 T cells play in coordinating the overall
immune response. MHCI, on the other hand, is expressed on all nucleated cells, which allows
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presentation of peptide to primed CD8 T cells in all tissues and almost all cell types in the body,
a beneficial feature as it allows removal of any nucleated cell that has been infected or has
mutated. Thus, CD4 and CD8 T cells act on different cell types to exert their effector or helper
functions.
After priming, T cells need to traffic to the site of infection, which is achieved through
chemokine and chemokine receptor pairing. Primed T cells upregulate receptors that allow them
to enter into the bloodstream and subsequently the site of inflammation. Entry into the
bloodstream is facilitated by sphingosine-1-phosphate (S1P)- S1P receptor (S1PR) interaction,
where the blood maintains a high level of S1P which draws in primed T cells that have
upregulated S1PR as a consequence of activation13. Tissue and innate immune cells at the site of
infection produce chemokines that recruit T cells in a context-specific manner14. Once T cells
enter the tissue, they recognize cognate p:MHC II either on the surface of professional APCs for
CD4 T cells, or on the surface of infected nucleated cells, hematopoietic or non-hematopoietic,
for CD8 T cells, to exert help or effector functions.
In summary, T cell response is highly regulated following pathogen invasion. T cell
priming is tightly controlled to allow prompt activation when needed and avoidance of
unnecessary activation to maintain homeostasis. Engagement of primed T cells with cognate
p:MHC is controlled by design so that CD4 help is limited to professional APCs and
infected/mutated cells across all tissues can be promptly removed by CD8 T cells. Regulation at
the priming phase and later in the effector phage allow mounting of a T cell response that’s
appropriate in terms of magnitude and quality.
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1.3 T cell immunity in acute infection and vaccination
models
CD8 T cells following priming develop into cells with various degrees of cytotoxicity
and memory potentials15,16. This heterogeneity is at least partially achieved during priming,
where the DCs present p:MHC to the CD8 T cells in a structure called the immune synapse17. It
has been shown that the pole proximal to the immune synapse and the pole distal to it of the CD8
T cells have differential distribution of surface and intracellular molecules. Consequently, after
the first cell division, the two daughter cells acquire an unequal amount of cytokine receptors and
effector molecules. At the height of clonal expansion, some CD8 T cells express elevated levels
of transcription factors RUNX3, T-bet and Eomesdermin (Eomes) that promote a cytotoxic
phenotype, and express high level effector molecules IFN γ, granzymes and perforin15,18,19. In
contrast, some CD8 T cells exhibit lower cytotoxicity and higher levels of molecules associated
with memory cells such as the chemokine receptor IL7Ra and pro-survival transcription factor
Bcl-220. Following antigen clearance, the highly cytotoxic CD8 T cells quickly contract and are
thus termed as short-lived effector cells (SLECs). Whereas the less cytotoxic effector CD8 T
cells that express memory markers contract less and are better at generating memory, and these
effector cells are thus called memory precursor cells (MPECs). MPECs give rise to memory cells
that can survive without antigen stimulation and quickly proliferate and differentiate into new
SLECs and MPECs upon secondary antigen encounter. In this way, the CD8 T cell response
achieves both prompt antigen control and memory formation upon pathogen invasion.
CD4 T cells play a central role in coordinating innate and adaptive immunity and achieve
this goal through a high level of plasticity, which is the ability to differentiate down multiple
pathways . In response to signals through TCR, co-stimulation, and cytokines provided by DCs,
7

CD4 T cells differentiate into subtypes that provide contact-dependent help or context-specific
7

cytokines to coordinate response of the innate immune cells, CD8 T cells, as well as B cells.
CD4 T cells that specialize in providing B cell help migrate from the T cell zone to the B cell
zone and are called follicular helper T (Tfh) cells21, where they promote the expansion and
affinity maturation of B cells which eventually leads to high-affinity neutralization antibody
production. Differentiated non-Tfh CD4 T cells are collectively called non-Tfh effector cells, and
depending on the types of infection and the cytokine milieu during priming, the effector CD4 T
cells can take the form of a Th1, Th2 or Th17, which mounts appropriate response against
intracellular pathogens, helminth/parasites, or extracellular pathogens, respectively. Like CD8 T
cells, the antigen-specific CD4 T cell population also contracts and gives rise to memory CD4 T
cells following antigen clearance22,23. Memory CD4 T cells, like memory CD8 T cells, are
capable of antigen-free survival as well as prompt proliferation and differentiation upon
rechallenge.
In summary, the T cell response following acute infection or vaccination accomplish two
goals, to generate enough cells with effector functions that allow prompt pathogen control, and to
produce memory that protects against future encounters with the same pathogen.

1.4 T cell response in the presence of persistent antigens
T cell responses differ when the antigens persist for an extended period of time in
scenarios such as chronic hepatitis C virus (HCV) infection for humans, chronic strains of
lymphocytic choriomeningitis virus (LCMV) for mice, transplantations, and various kinds of
tumors. In these cases, T cells are under persistent antigen exposure and undergo an alternative
differentiation pathway24–27.
The altered CD8 T cell response in the presence of persistent antigens has been heavily
studied and is termed exhaustion, which is thus named based on their prolonged expression of
8

inhibitory receptors such as PD-1 and TIM3, decreased cytokine production such as IFN-γ and
TNF, and blunted proliferation compared to their acute counterparts during the chronic phase of
the infection28–31. Like cytotoxicity for CD8 T cells during the acute infections, exhaustion also
exists as a spectrum with CD8 T cells occupying various positions on that spectrum . While
32

some CD8 T cells are terminally exhausted with multiple inhibitory receptor expression and little
turnover, some CD8 T cells are less exhausted and carry more effector functions. Despite the
connotation of the term exhaustion, a protective role of the exhausted CD8 T cells have been
demonstrated, as depletion of CD8 T cells has been shown to exacerbate infection control and
tumor control in various models31,33. In summary, exhausted CD8 T cells are a heterogeneous
group and despite their name those exhausted CD8 T cells are required for active pathogen
control.
In recent years, the mechanism of the durable CD8 T cell response is in part worked out
through the discovery of a memory-like CD8 T cell population (progenitor exhausted, or
TPEX)34,35. TPEX are less exhausted, more quiescent, and require the transcription factor TCF-1
which is required for CD8 memory formation. This CD8 subset mostly resides in the T cell zone
as opposed to the red pulp in the spleen and is thought to be more shielded from antigen
exposure35. They demonstrate superior proliferation and differentiation capacity in a transfer
setting, and, importantly, PD-1 blockade acts on the TPEX population by facilitating their
mobilization and differentiation into cells with more effector functions. In contrast to TPEX,
CD8 T cells that have lost TCF-1 expression acquire a higher cytotoxic or exhaustion phenotype.
Because they are terminally differentiated and contract quickly35, those TCF-1– cells are thought
as short-lived like SLECs and need constant replenishment. Based on those observations, the
TPEX cells are thought to replenish the more exhausted CD8 T cell pool, thus maintaining a
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durable CD8 T cell response in the presence of persistent antigens. This progenitor-progeny
relationship is initially worked out in LCMV-c13, and subsequently has been observed in tumors
and autoimmunity models .
36

However, much remains to be learned about the CD8 T cell response in the presence of
persistent antigens. If TCF-1+ TPEX is quiescent in vivo, it is unlikely that there is frequent
mobilization from the TPEX to the more exhausted cells, which leaves the question how exactly
CD8 T cell dynamics is maintained. It is also unclear what the CD8 subset are that carry more
effector functions. My first part of the thesis project attempts to tackle this question of CD8
population dynamics and heterogeneity.
Similar to CD8 T cells, activated CD4 T cells are also required for pathogen control and
demonstrate altered phenotypes in the presence of chronic antigens. Our current knowledge of
the altered CD4 T cell response is largely derived from studies using LCMV-c13. Compared to
their acute counterparts, the inhibitory receptor expression of CD4 T cells is higher, leading
some groups to also describe them as being exhausted37,38. Although producing less IL-2
compared to their acute counterparts and thus delivering less help to CD8 T cells and effector
CD4 T cells, these CD4 T cells produce a higher level of IL-21, which help maintain the CD8 T
cell response that is required for the control of the virus39–41. CD4 T cells in chronic infection also
produce more IL-10, which is thought to be driven by the transcription factor BLIMP-1 that
promotes terminal effector differentiation and antagonizes the transcription factor BCL-642. IL10 is thought to be immunoregulatory and mice lacking IL-10 are capable of clearing LCMV-c13
within the first 9 days post infection43. However, it is unclear if IL-10 might play some beneficial
role once the chronic infection sets in by mechanisms such as protecting the hosts from overt
immunopathology or preserve the CD8 T cells from getting more exhausted, a phenomenon that
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has been described in anti-tumor immunity and another chronic strain of IL-1044–46. There is also
a bias toward cells that express Bcl6 and CXCR547, in line with a need for continued Tfh activity
that promotes production of high-affinity neutralizing Abs, which is required for the eventual
clearance of the virus. Aside from those aforementioned info, little is known about how the CD4
T cell response to persistent antigens is coordinated or how such a response is maintained,
despite the crucial role CD4 T cells play in chronic viral infections, which is what motivates the
second part of my thesis project.
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Chapter 2: Identification of a CX3CR1 expressing exhausted
CD8 T Cell Subpopulation

The contents of this chapter have been previously published in Journal of Immunology.
Raju, S.*, Xia, Y.*, Daniel, B., Yost, K. E., Bradshaw, E., Tonc, E., Verbaro, D. J., Kometani,
K., Yokoyama, W. M., Kurosaki, T., Satpathy, A. T., & Egawa, T. (2021). Identification of a
T-bethi Quiescent Exhausted CD8 T Cell Subpopulation That Can Differentiate into
TIM3+CX3CR1+ Effectors and Memory-like Cells. Journal of Immunology, 206(12), 2924–
2936. PMID: 34088768 (*: equal contribution).

2.1 Abstract
Persistent Ag induces a dysfunctional CD8 T cell state known as “exhaustion”
characterized by PD-1 expression. Nevertheless, exhausted CD8 T cells retain functionality
through continued differentiation of progenitor into effector cells. However, it remains illdefined how CD8 T cell effector responses are sustained in situ. In this study, we show using the
mouse chronic lymphocytic choriomeningitis virus infection model that CX3CR1+ CD8 T cells
contain a T-bet–dependent TIM3−PD-1lo subpopulation that is distinct from the
TIM3+CX3CR1+PD-1+ proliferative effector subset. The TIM3−CX3CR1+ cells are quiescent and
express a low but significant level of the transcription factor TCF-1, demonstrating similarity to
TCF-1hi progenitor CD8 T cells. Furthermore, following the resolution of lymphocytic
choriomeningitis virus viremia, a substantial proportion of TCF-1+ memory-like CD8 T cells
show evidence of CX3CR1 expression during the chronic phase of the infection. Our results
suggest a subset of the CX3CR1+ exhausted population demonstrates progenitor-like features
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that support the generation of the CX3CR1+ effector pool from the TCF-1hi progenitors and
contribute to the memory-like pool following the resolution of viremia.

2.2 Introduction
Upon encountering Ag, naive CD8 T cells undergo robust clonal expansion and acquire
effector functions for host protection against pathogens and tumors. However, in the context of
persistent Ag exposure during chronic viral infections, they are subject to alternative
differentiation known as T cell exhaustion, which is characterized by the continued expression of
inhibitory receptors, decreased cytokine secretion, and blunted proliferation1, 2. Nevertheless,
exhausted CD8 T cells are not inert and can actively control Ag burden3. This function is in part
facilitated by a progenitor–progeny relationship within exhausted CD8 T cells that facilitates
sustainable generation of functional effector cells. However, our understanding of the progenitor
cell dynamics that supports this continuous differentiation process is limited.
The TCF-1hi (CXCR5+Ly-108/SLAMF6+) progenitor exhausted CD8 T cells (TPEX)
give rise to TCF1− effector-like cells, of which a substantial fraction expresses the inhibitory
receptor/exhaustion marker TIM34-8. CX3CR1 is also expressed in a subset of TCF-1− effectorlike cells, which exhibit enhanced proliferative activity and cytolytic function compared with
CX3CR1− cells 9, 10. Because TPEX cells are quiescent in situ and mainly present in the white
pulp of the spleen and are thus physically separated from red pulp–predominant TCF-1lo/− cells 4,
it is possible that proliferative CX3CR1+ CD8 T cells are supported by a non-TPEX intermediate
progenitor population. Prior work identified T-bet–expressing exhausted CD8 T cells as having
progenitor-like features with a low intrinsic turnover 11; however, their relationship to TCF1hi TPEX cells remains unclear as a vast majority of TPEX express T-bet at a low level. The
CX3CR1+ population is enriched for T-bet–expressing cells compared with TCF-1hi TPEX cells
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4,5

, suggesting that they could be composed of a progenitor-like subpopulation, even though they

lack cells with high TCF-1 expression.
In this work, we found using single-cell RNA sequencing (RNA-seq) (scRNA-seq) that
CX3CR1+ cells are composed of two clusters. Cells present in one of the CX3CR1+ cell clusters
are quiescent, highly enriched for expression of T-bet, and distinguished from the proliferating
cluster of CX3CR1+ cells by TIM3 expression. The quiescent cluster also resembles TPEX cells
by basal expression of Tcf7 and Bach2, the transcription factor genes highly expressed in TPEX.
Slow replenishment of the total CX3CR1+ cells by CX3CR1− cells, dependency on the
transcription factor T-bet, and trajectory based on scRNA-seq diffusion pseudotime analysis
suggest that TIM3−CX3CR1+ cells serve as upstream precursors for the
TIM3+CX3CR1+ effector-like cells. By contrast, the resistance of a vast majority of
TIM3+ CX3CR1− cells to T-bet deletion and CD4 T cell depletion suggests that they are
independent of CX3CR1+ cells or develop through an alternative pathway. Furthermore, a
substantial fraction of TCF-1hi “memory-like” cells that persist after the resolution of viremia are
marked by a history of Cx3cr1 expression during high viral burden and display continued
expression of CX3CR1 and the exhaustion-associated gene TOX. These results collectively
suggest multiple trajectories of CD8 T cell differentiation dynamics under exhausting conditions
and the development of memory-like cells that persist after the resolution of viremia 12-14.

2.3 Results
CX3CR1 defines two populations of exhausted CD8 T cells with distinct properties
We first sought to identify additional heterogeneity in the CX3CR1+ subset, given that
they are enriched for T-bet–expressing cells11.To this end, we performed scRNA-seq analysis of
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LCMV gp33–specific CD8 T cells during the chronic phase of LCMV-c13 infection in C57BL/6
mice. UMAP of the data demonstrated four major clusters of exhausted CD8 T cells, including
the previously defined TCF-1hi (encoded by Tcf7) and TIM3 (Havcr2)+ subsets, and also two
distinct clusters of Cx3cr1+ cells segregated by the expression of Havcr2 (Figs. 1A, 2A).
Consistent with the scRNA-seq data and prior reports 10, 23, ∼40% of LCMV-gp33–specific CD8
T cells in mice infected with LCMV-c13 expressed CX3CR1 in the chronic phase, and its
expression was seen exclusively in TCF-1lo/− cells (Figs 1B, 2B) The frequency of
CX3CR1+ cells was notable in both TIM3− and TIM3+ cells, confirming the presence of two
unique CX3CR1+ populations (Fig. 1C). We also observed TIM3−CX3CR1−TCF1lo/− population;
however, this subset was not a focus for the rest of this study (Fig. 1C).
The amount of surface PD-1 expression is known to correlate with the extent of
exhaustion, with higher levels corresponding to more severe exhaustion and unresponsiveness to
the checkpoint blockade 11, 24, 25. Notably, the surface PD-1 level in TIM3−CX3CR1+ cells was
even lower than that in TCF-1hi TPEX cells (Fig. 1D). PD-1 was elevated in the TIM3+ fraction
of CX3CR1+ cells, suggesting that TIM3+CX3CR1+ cells are more differentiated or in a more
activated state than TCF-1hi and TIM3−CX3CR1+ cells. Accordingly, the expression of GZMB
was significantly higher in TIM3+CX3CR1+ cells compared with TIM3−CX3CR1+ cells, whereas
GZMB expression was barely detectable in TCF-1hi cells (Fig. 1E)
We next examined cell cycle states between the two CX3CR1+ populations by measuring
BrdU incorporation, which directly reflects DNA synthesis during the S phase of the cell cycle,
by pulse labeling in the chronic phase (22 dpi) of LCMV-c13 infection (Fig. 1F) We confirmed
the quiescence of TCF-1hi cells as <5% of cells incorporated BrdU over 12 h following one
injection of BrdU. TIM3+CX3CR1+ cells exhibited the highest incorporation of BrdU (∼30%),
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whereas BrdU incorporation by the TIM3−CX3CR1+ cells was significantly lower than the
TIM3+ counterpart, which was also reflected in Ki-67 expression (Fig. 2C). However, at an
earlier time point on 8 dpi, cells in all subpopulations, including TPEX and
TIM3−CX3CR1+ cells, were active in the cell cycle and upregulated Nur77 (Fig. 2C, 2D).
Notably, expression of Nur77 in TIM3−CX3CR1+ cells was slightly lower (Fig. 2D), suggesting
that they equally or slightly weakly received a TCR stimulus following infection. These results
highlight distinct characteristics between the two subpopulations of CX3CR1+PD-1+ CD8 T
cells. Whereas TIM3+ CX3CR1+ cells are actively proliferating effector cells similar to the cells
described in previous studies 9,10, TIM3−CX3CR1+ cells appear progenitor-like, with phenotypic
similarities to TPEX with regards to low to moderate cell cycle activity and low expression of
PD-1 and GZMB, and are thus distinct from TIM3+CX3CR1+ cells.
Effector cells are typically found in both blood and tissue at higher frequencies compared
with memory-like cells26. To examine the migratory behavior of CX3CR1+ cells, we performed
in vivo labeling of T cells by an i.v. injection of anti-CD45.2, which allowed us to discriminate
between tissue resident (CD45.2−) and circulating (CD45.2+) Ag-specific CD8 T cells present in
the lung. In contrast to TIM3+CX3CR1− cells that were predominantly localized in the lung
parenchyma, distribution of both CX3CR1+ subpopulations was significantly enriched in the
circulating compartment (Fig. 2E) Within the CX3CR1+ populations, more TIM3+ cells were
found in the tissues compared with TIM3− cells, suggesting that TIM3+CX3CR1+ cells
preferentially migrate or are retained in tissue parenchyma and are likely key mediators of
effector function.
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TIM3−CX3CR1+ cells can give rise to TIM3+CX3CR1+ effectors
To examine the development and dynamics of each subset, we next performed a timecourse analysis. In the early phase of the acute phase response on 5 dpi, the
TIM3+CX3CR1− subset was dominant; however, CX3CR1+ cells were present with uniformly
intermediate TIM3 expression without a clear segregation between TIM3− and
TIM3+ populations (Fig. 3A, B). TIM3−CX3CR1+ cells emerged around 8 dpi, and they
continued to increase in numbers until 15 dpi, possibly because a subset of Ag-specific CD8 T
cells receive weaker TCR stimulus and slow down their proliferation during this period (Figs.
2C, 2D, 3A, 3B).
To gain additional insight into the two CX3CR1+ populations of CD8 T cells, we purified
the two subsets of CX3CR1+PD-1+ CD8 T cells based on TIM3 expression as well as TPEX and
terminally exhausted (TIM3+CX3CR1−) CD8 T cells for population-based RNA-seq on 16 dpi.
Confirming our scRNA-seq data, PCA and K-means clustering showed that the two
CX3CR1+ populations have distinct gene expression patterns (Figs. 4A, 5A). A gene set
enrichment analysis for differentially expressed genes between the two CX3CR1+ populations
showed significant representation of pathways associated with cell division, MYC target genes,
IL2–STAT5 signaling, and GTPase effectors, consistent with effector functions, high
proliferative activity, and tissue migration (Fig. 5B). This result was supported by a gene-level
analysis showing Gzmb, Prdm1, Ifng, Prf1, Lag3, Entpd1 (CD39), and Tigit being higher in
TIM3+CX3CR1+ compared with the TIM3−CX3CR1+ populations (Fig. 5C). In addition, Kmeans clustering showed that many genes that are differentially expressed between the
CX3CR1+ populations were similarly expressed between TPEX and TIM3−CX3CR1+ cells (Fig.
5A, clusters 2 and 5), suggesting that there is transcriptomic similarity between TPEX and

22

TIM3−CX3CR1+ cells. Among genes encoding transcription factors, the two
CX3CR1+ populations expressed high Tbx21 compared with the TPEX subset that is marked by
high expression of Tcf7, Id3, Bcl6, and Bach2. It is notable that these TCF-1hi population–
specific factors were also expressed at lower but significant levels in the
TIM3−CX3CR1+ population, whereas the TIM3−CX3CR1+ population expressed higher amounts
of Zeb2, which cooperates with T-bet 27, 28, than TIM3+CX3CR1+ cells and other PD-1+ CD8 T
cells (Fig. 4B). Consistently, TCF-1 protein was also expressed in a fraction of gp33-specific
TIM3−CX3CR1+ CD8 T cells, and the frequency of TCF-1+ cells was substantially reduced in
TIM3−CX3CR1+ cells (Figs. 2B, 4C).
To assess the differentiation potentials of CX3CR1+ CD8 T cells, we transferred CFSElabeled TIM3− and TIM3+CX3CR1+ and SLAMF6+TIM3− (TPEX) CD8 T cells isolated from
LCMV-c13–infected C57BL/6 mice (CD45.2) into infection-matched congenic CD45.1 mice
and analyzed donor-derived cells 14 d after transfer (Fig. 4D). Approximately 40% of donorderived TIM3−CX3CR1+ cells upregulated TIM3 (Fig. 4E, F), and TIM3 upregulation
preferentially occurred in CFSElo cells (Fig. 4H). In addition, the majority of CFSEmid and a
fraction of CFSElo cells remained as TIM3− (Fig. 4E, H). TIM3+CX3CR1+ cells barely generated
TIM3− cells (Fig. 4E-G). However, expansion of both TIM3− and TIM3+ CX3CR1+ cells was 2–
3-fold lower compared with TPEX cells, which gave rise to more differentiated cell types.
Inefficient differentiation to CX3CR1− cells from the transferred TPEX could be affected by
timing or a complication in trafficking or cell death in a setting of infection-matched adoptive
transfer. It is also notable that expansion of TIM3+CX3CR1+ cells is substantially compromised
upon adaptive transfer, although they were highly proliferating in situ. To gain additional
insights, we treated LCMV-infected mice with anti–PD-L1 Abs, which releases TPEX from PD-
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1–mediated suppression and specifically drives their expansion (Fig. 3D, E)4. After three doses
of anti–PD-L1, we detected proportional ratios between TIM3− and TIM3+ CX3CR1+ cells,
suggesting that proliferating TPEX cells give rise to both populations in situ (Fig. 3D, E). These
results collectively indicate that TIM3−CX3CR1+ cells can be derived from TPEX and
differentiate into TIM3+CX3CR1+ cells. This result was also supported by diffusion pseudotime
analysis of scRNA-seq data, showing a trajectory of TPEX differentiation toward
TIM3+CX3CR1+ cells via a TIM3−CX3CR1+ intermediate (Fig. 4H). These results suggest that
TIM3− cells are positioned at an intermediate between TPEX and upstream of TIM3+ cells in
terms of developmental hierarchy within the CX3CR1+PD-1+ CD8 T cells.
The loss of CD4 help via IL-21 reduces the absolute numbers of CX3CR1+ CD8 T cells
during the chronic phase of the response to LCMV-c13 infection 10. In CD4-depleted LCMVc13–infected mice, we did not observe a reduction in the number of CX3CR1+ CD8 T cells on 8
dpi at the peak of the Ag-specific CD8 T cell response (Fig. 4A, C). However, in the chronic
phase on 22 dpi, the number of CX3CR1+ CD8 T cells in CD4-depleted mice was substantially
reduced in both TIM3− and TIM3+ subpopulations, which is consistent with prior results 10 (Fig.
4A, C). Thus, CD4 T cell help appears to be required for the maintenance of the CX3CR1+ cells
rather than their generation. Interestingly, the loss of TIM3−CX3CR1+ CD8 T cells preceded that
of TIM3+ cells, with an ∼15-fold reduction of the former population compared with an ∼4-fold
reduction of the latter on 15 dpi. The severe loss of TIM3+CX3CR1− cells followed by
TIM3+CX3CR1+ cells could reflect their developmental relationship or highlight differential
sensitivity to IL-21 for their maintenance.
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T-bet is critical for the maintenance of CX3CR1+ exhausted CD8 T cell populations
To more rigorously test the possibility that the TIM3−CX3CR1+ population overlaps the
previously identified T-bethi progenitor population 11, we first examined the proportion of each
subset with T-bethi cells by flow cytometry. Indeed, TIM3−CX3CR1+ cells comprised ∼40% of
total T-bethi cells followed by the TCF-1hi population (30%) (Fig. 6A). Co-staining for T-bet and
EOMES showed a marked difference in T-bet and EOMES expression between the two
CX3CR1+ populations (Fig. 6B). Notably, the TIM3−CX3CR1+ subset was predominantly
composed of T-bethi cells (∼70%) compared with the rest of the exhausted CD8 T cell subsets, in
which a majority of cells were EOMEShi but T-betlo (Fig. 6B). Together with low PD-1
expression, basal expression of TPEX-associated transcription factors, low proliferative activity,
and capacity for differentiation to TIM3+ effector/exhausted cells, our data suggest that
TIM3−CX3CR1+ CD8 T cells overlap with the previously reported T-bethi progenitor cells 11.
The loss of T-bet in T cells during chronic infection has been associated with more severe
exhaustion 11, 29. To determine whether T-bet is required for TPEX, T-bethiTIM3−CX3CR1+, cells
or both, we analyzed CD8 T cell responses to LCMV-c13 infection in mice with CD8 T cell–
specific Tbx21 deletion. During the chronic phase of LCMV infection (29 dpi), frequencies of
total LCMV gp33-specific CD8 T cells in the spleen were reduced by 2.5-fold in CD8cre Tbx21F/F mice compared with control cre(−) Tbx21F/F mice (Fig. 6C, 6D). The absolute
number of TPEX cells did not significantly change by CD8 T cell–specific deletion of Tbx21. In
contrast, the reduction of total Ag-specific CD8 T cells was attributed to a marked reduction of
CX3CR1+ CD8 T cells, most notably to that of TIM3−CX3CR1+ cells that expressed the highest
amounts of T-bet among all fractions (Fig. 6B, 6D). We also observed a decreased frequency and
absolute number of TIM-3+CX3CR1+ effector-like cells, which could reflect the loss of input
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from TIM3−CX3CR1+ cells or defective differentiation of TPEX cells. Consistent with previous
studies 11, 30, 31, ex vivo stimulation of splenocytes from Tbx21-deficient mice showed preserved
GZMB expression, with decreased IFN-γ expression in CD8 T cells, which likely contributes to
defective viral control (Fig. 7A–D). To determine the impact of the loss of CX3CR1+ CD8 T
cells on viral control, we tracked LCMV-c13–infected CD8-cre+ Tbx21F/F and
control Tbx21F/F mice for 100 d, by which time the majority of immune-competent mice resolve
viremia 32. Although control mice were able to resolve viremia, Tbx21-deficient mice still
demonstrated significant viremia (Fig. 6E). These results indicate that T-bet is required for the
maintenance of CX3CR1+ cells despite a minimal impact on TCF-1hi cells.

Eomes and Bach2 antagonistically control differentiation of TPEX into effector-like
exhausted CD8 T cells
We next defined the relationship between the TCF-1hi and CX3CR1+ populations by
examining the function of transcription factors that are highly expressed in and potentially
important for differentiation of the TPEX population. Based on our gene expression data (Fig.
4B), we first examined the role of Eomes in the differentiation of CD8 T cells during the chronic
phase of LCMV infection. Eomes expression has been associated with severe exhaustion, and its
loss results in reduced Ag-specific CD8 T cells numbers 11, 33. We thus anticipated
that Eomes deletion would result in a reduction in TCF-1hi cells. Contrary to our prediction,
in CD8-cre+EomesF/F mice, there was a 3-fold increase in both frequency and absolute numbers
of total LCMV-gp33–specific CD8 T cells (Fig. 8A, 8B). We suspect our result is discrepant
with the prior results of Eomes deficiency, possibly because of an additional deletion of Eomes
in CD4 T cells using CD4-cre in prior studies, whereas the increased proportion of TPEX is
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consistent with the reported reduced Prdm1 expression in Ag-specific CD8 T cells 11, 34. This
increase was most attributable to a >7-fold increase in TPEX cells (Fig. 8B). In addition,
TIM3−CX3CR1+ CD8 T cells were increased by 3-fold (Fig. 8A, 8C). However, we did not
observe a change in the total TCF-1lo/−PD-1+ CD8 T cells or TIM3+CX3CR1+ CD8 T cells, and
within TCF-1lo/− cells, TIM3 cells were increased in number (Fig. 8A, 8C). Increased numbers of
the two quiescent subpopulations of exhausted CD8 T cells in Eomes deficiency suggest that
EOMES promotes the development of TPEX cells after T cell activation and/or represses the
differentiation of progenitor-like CD8 T cells, including TPEX and TIM3−CX3CR1+ cells, to
downstream effector cells.
As a consequence of altered differentiation, the turnover of downstream effector cells
derived from TPEX cells or TIM3−CX3CR1+ cells may be impaired, and fitness of these effector
cells could be compromised in Eomes-deficient mice. To test this possibility, we first examined
IFN-γ and TNF-α production by CD8 T cells following the stimulation of splenocytes with
LCMV-specific peptides ex vivo, which showed no difference between Eomes-deficient and
control CD8 T cells (Fig. 7E, 7F). However, we observed a significant reduction of GZMB
expression in Eomes-deficient Ag-specific CD8 T cells (Fig. 7G, 7H). Consistent with the
defects in differentiation of PD-1+ CD8 T cells, the majority of CD8-cre EomesF/F mice failed to
resolve viremia on ≥100 dpi (Fig. 7I). These results together indicate unique roles of the two Tbox proteins, T-bet and EOMES, in CD8 T cell responses to persisting Ag and a specific role for
T-bet in the maintenance of CX3CR1-expressing cells.
Bach2 is another transcription factor highly expressed specifically in TPEX cells. CD8 T
cell–specific deletion of Bach2 resulted in a similar increase in the number of gp33-specific CD8
T cells to Eomes deletion (Fig. 8D–G). However, the overall increase was attributable to TCF-
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1lo/− cells with a marked reduction in the frequency of TPEX as well as absolute numbers. In
TCF-1lo/− cells, contrary to Eomes-deficient mice, the most notable increase was seen in the
TIM3+CX3CR1+ proliferating population. These results indicate that, although both EOMES and
BACH2 are highly expressed in the TPEX population, their roles may be antagonistic with
BACH2-protecting TPEX cells from differentiation into the downstream effector cells.

CX3CR1+ CD8 T cells are largely self-sustainable with limited input from TPEX cells
We next sought to measure the turnover of the CX3CR1+ cells by TCF-1hi TPEX-derived
cells by performing genetic labeling of CX3CR1+ cells by using the Cx3cr1-creERT2 allele
crossed to the ROSA26-loxP-stop-loxP-tdTomato (R26tdT) reporter (Fig. 9A). Then, 16 h after
one dose of TAM on 8 dpi, it showed labeling of ∼10–25% of TCF-1lo/− CD8 T cells in contrast
to the little labeling of TPEX cells in the spleen, demonstrating specific, low-background
labeling of TPEX cells by the TAM-inducible cre activity (Fig. 9B). Then, 48 h after TAM
administration, ∼80% of CX3CR1+ CD8 T cells in the peripheral blood became tdT positive
(Fig. 9C). Given that TPEX cells can differentiate into downstream effector and exhausted CD8
T cells, we expected to observe robust displacement of tdT+ cells by TPEX-derived tdT− cells
within the CX3CR1+ populations over the course of the antiviral response. However, over a 2-wk
chase period, when TAM is no longer bioavailable in vivo 35, 36, the frequencies of tdT+ cells in
the CX3CR1+ CD8 T cells were preserved with only a modest decay to 60% on 22 dpi (Fig. 9C).
In the spleen, both TIM3− and TIM3+CX3CR1+ cells retained high percentages of tdT+ cells,
whereas ∼30% of TIM3+CX3CR1− cells were labeled with tdT (Fig. 9D), suggesting some
transition from CX3CR1+ into CX3CR1− cells. These results highlight a slow turnover of
CX3CR1+ cells, which could reflect a long population half-life or be consistent with a relatively
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minor contribution of TPEX cells to the pool of TIM3− and TIM3+CX3CR1+ exhausted CD8 T
cell pool.

CX3CR1+ cells exhibit longevity following viral clearance with the capability to respond to Ag
rechallenge
In immunocompetent mice, LCMV-c13 viremia is eventually resolved by both T and B
cell responses around 3 mo after infection 16, 32, 37. We next sought to determine the long-term
fate of CX3CR1+ cells as the TIM3−CX3CR1+ subset expressed low but detectable levels of the
memory-related factor, Tcf7. To this end, we administered TAM to Cx3cr1-creERT2 R26tdT
mice during the chronic phase of infection on 28 dpi and chased the tdT-labeled cells for 120 d.
Similar to acute LCMV infection, we were able to detect the persistence of LCMV-gp33–
specific CD8 T cells expressing intermediate levels of PD-1 in the PBMCs and in the spleen of
LCMV-c13–immune mice (Fig. 10A). These cells likely correspond to “chronic memory” cells
or memory-like cells that were previously reported 14, 38. In contrast to LCMV-Arm–immune
mice, in which TCF-1hi memory CD8 T cells were mostly CX3CR1−, a substantial fraction of
gp33-specific chronic memory CD8 T cells in LCMV-c13–infected mice showed an effector
memory phenotype with the expression of CX3CR1 (Fig. 10A). TAM administration to LCMVc13–infected Cx3cr1-creERT2 fate-mapping mice on 28 dpi resulted in the marking of ∼40% of
LCMV-gp33–specific CD8 chronic memory T cells on 120 dpi (Fig. 10A, 10B). Almost all
tdT+ cells continued to express surface CX3CR1, and ∼40% of the tdT+ cells expressed the
memory transcription factor TCF-1 at the levels slightly lower than the CX3CR1− chronic
memory cells (Fig. 10A, 10B). The majority (∼80%) of CX3CR1+ chronic memory CD8 T cells
were also tdT+ and thus were derived from CX3CR1+ cells during the labeling period (Fig. 10B).
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In contrast to PD-1+ CD8 T cells during high Ag burden, the CX3CR1+ and CX3CR1− chronic
memory CD8 T cells were able to produce considerable IFN-γ following stimulation with
LCMV-gp33 ex vivo (Fig. 10C). Notably, ∼50% of IFN-γ+ cells also expressed TNF-α,
indicating partial restoration of polyfunctionality in these chronic memory CD8 T cell
populations (Fig. 10C). The transcription factor TOX has been closely linked to CD8 T cell
exhaustion in the context of antiviral and anti-tumor immunity and is implicated in programming
the unique genetic and epigenetic signatures associated with chronic Ag stimulation 39-43.
Interestingly, the vast majority of chronic memory CD8 T cells continued to express TOX (Fig.
10D). Their TOX expression was lower than that of TCF-1+ progenitors during active infection,
which mirrors continued expression of low PD-1 by chronic memory CD8 T cells38.
Furthermore, both CX3CR1+ and CX3CR1− chronic memory CD8 T cells from LCMV-c13–
infected mice were capable of secondary expansion following adoptive transfer to congenic wildtype mice followed by LCMV-Arm infection (Fig. 10E). Because CX3CR1+TCF-1+ cells barely
expressed TIM3 after the resolution of viremia (data not shown), it is likely that a substantial
fraction of CX3CR1+ chronic memory CD8 T cells is derived from the TCF1lo/−TIM3−CX3CR1+ cells or a minor population of TPEX, which had turned on expression
of Cx3cr1 as they initiated differentiation toward TCF-1lo/− cells. These results collectively
indicate that a substantial fraction of Ag-experienced TCF-1+ cells are derived from exhausted T
cells that initiated differentiation away from TPEX, suggesting the plasticity for long-term
persistence, polyfunctionality, and secondary expansion after chronic exposure to Ag
and Tcf7 downregulation.

30

2.4 Discussion
The mechanisms underlying the maintenance of functional CD8 T cell responses in the
context of persistent Ag exposure remains unresolved. A substantial body of work has identified
various subsets of exhausted CD8 T cells with distinct phenotypic and gene expression profiles.
However, how these populations interact and ultimately promote control of viral or tumor burden
remains an active area of investigation. In this study, we identify a TIM-3 negative subset of PD1lo CD8 T cells within the CX3CR1+ population, which is highly enriched for T-bethi cells. This
population is quiescent and exhibits low TCF-1 expression but also demonstrates features of
effector-like cells. These results highlight underappreciated heterogeneity within exhausted CD8
T cells and provide a more complete framework for understanding the dynamics of T cell
responses to chronic Ag.
Prior work has established that TCF-1hi TPEX cells act as progenitors for BLIMP1+ effector-like and terminally exhausted CD8 T cells. In comparison, an analogous relationship
was described between T-bethi cells (progenitor) and Eomeshi cells (progeny), which become
fully exhausted as Eomes expression elevates 11, 29. However, the nature of the T-bethi progenitor
cells has remained unclear because TCF-1hi TPEX cells are predominantly T-betloEOMEShi 4.
Two recent papers described a subset of PD-1+ CD8 T cells enriched for CX3CR1 expression
and T-bet 9, 10. These cells are highly proliferative and express effector molecules, which
contribute to the control of chronic viral infection and tumors. They also overlap with another
subpopulation of exhausted CD8 T cells, Ly108(SLAMF6)−CD69−TEX-int cells, which are
proposed to be a transitory population between TPEX and terminally exhausted cells 44. Our
work has identified a TIM3-negative subpopulation within the CX3CR1+ population, which is
almost exclusively T-bethi cells and distinct from the transitory populations in their cell cycle
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status and gene expression. The TIM3− cells are phenotypically similar to TPEX with their
quiescence, basal expression of TCF-1, and low levels of effector gene expression. Because each
study used different markers to define populations and phenotypic changes, further work will be
necessary to reconcile the discrepancies between the studies. In addition, although not a focus of
this study, we identified a TIM3−CX3CR1−TCF1lo/− population whose function and development
remain yet to be determined. This population was resistant to the loss of CD4 T cell help and
exhibited low proliferation. We speculate this could be an intermediate to TIM3+CX3CR1− cells,
which may develop from TPEX or naive CD8 T cells independent of CX3CR1+ cells.
A key question that remains unsettled is the developmental trajectory and nature of the
progenitor–progeny relationships between the exhausted CD8 T cell subsets. The external cues
that drive this process remain incompletely defined; however, a role for type I IFNs and IL-12 in
promoting differentiation has been proposed 6, 45, 46. This issue has been largely studied in the
setting of adoptive transfer of various subsets to congenic recipients. Indeed, adoptively
transferred TPEX cells exhibit higher proliferative potential than TCF-1− or CXCR5−PD-1+ CD8
T cells and can give rise to TIM3+ differentiated progeny 4-6. However, it should be noted that
the behavior of transferred cells may not faithfully reflect the kinetics of this transition in situ
because of inefficient engraftment of transferred cells that are removed from their native
microenvironment. This issue is also seen in long-term hematopoietic stem cells, which show a
limited contribution to homeostatic hematopoiesis, although they are capable of robust expansion
and reconstitution of cells in multiple lineages 47-49. This biology may also be the case in
exhausted CD8 T cells as exemplified by the loss of quiescence of TPEX cells upon adoptive
transfer and limited proliferative activity of TIM3+ CX3CR1+ cells in our study and TEX-int cells
in another study 44. In this study, we used an in vivo lineage-tracing approach to overcome this
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limitation and found that displacement of pulse-labeled CX3CR1+PD-1+ CD8 T cells by newly
generated cells derived from TPEX or naive CD8 T cells occurs slowly with a half-life longer
than a few weeks. This result suggests that, although transferred TPEX cells robustly give rise to
CX3CR1+ and CX3CR1− effector/exhausted CD8 T cells, they are mostly quiescent in situ and
do not rapidly replace downstream differentiated cells. This is consistent with low BrdU
incorporation and KI67 expression as well as a pseudotime modeling of our scRNA-seq data. We
recognize two caveats that need to be considered. First, we cannot rule out the possibility that a
small fraction of TCF-1hi cells that were labeled with tdT, instead of TCF-1lo/−CX3CR1+ cells,
replenish the CX3CR1+ CD8 T cell pool. However, this result also suggests that the vast
majority of TPEX, except for those with poised Cx3cr1 expression, are dormant with limited
contribution to TCF-1lo/− cells in situ, which is largely consistent with our interpretation. Second,
future work is necessary to evaluate TIM3−CX3CR1+ cells recruitment to TIM3+CX3CR1+ cells,
which is technically limited because of the lack of a specific cre driver. Nevertheless, given the
similarity to TPEX, TIM3−CX3CR1+ cells may function as intermediate progenitors for
TIM3+ CD8 T cells with limited self-renewing capabilities, like short-term hematopoietic stem
and progenitor cells, which are still dependent on largely dormant long-term hematopoietic stem
cells but mainly support homeostasis of hematopoiesis 47, 48.
The Ag-specific cells present in the host after the resolution of viremia no longer
demonstrate a high expression of PD-1 and have been termed chronic memory 14. Using our
CX3CR1 lineage-tracing approach, we were able to track cells labeled during the chronic phase
of the infection and found that a substantial portion of TCF-1+ chronic memory cells are labeled
by previous expression of CX3CR1 cells. The labeled cells are exclusively found in
CX3CR1+ chronic memory cells, suggesting earlier activation of Cx3cr1 imprints in its
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continued expression, which is consistent with trajectories of CX3CR1+ cells, and
TIM3−CX3CR1−TCF-1lo/− cells are mostly segregated during the chronic phase. Although we
cannot formally rule out that these labeled cells were derived from a small proportion of labeled
TPEX cells, it is unlikely this would be the case based on a much larger fraction of TCF1+ chronic memory cells being labeled by tdT. A previous study demonstrated that memory cells
that have experienced chronic Ag stimulation retain persistent PD-1 expression 38. Likewise, we
found that TCF-1+ cells generated through LCMV-c13 infection retain persistent TOX
expression, similar to effector memory cells or anti-CMV memory CD8 T cells in humans 12, 13,
50, 51

. These findings suggest that cells other than TPEX or central memory-like cells possess the

capacity to retain or re-express TCF-1 under certain conditions and highlight additional
heterogeneity of TCF-1+ CD8 memory T cells that may be imprinted by the kinetics of Ag
stimulation or inflammatory milieu. An equivalent type of memory T cell following cancer
elimination is likely 52, which may be important to prevent relapse. It remains to be determined
how this memory cell type differs from CX3CR1− memory cells through the acquisition of
imprinted identity during the effector phase. This knowledge will potentially transform into
methods that enhance long-term immunity against chronic viral infection or cancers.

2.5 Materials and Methods
Mice and infection
Male C57BL/6N and B6-CD45.1 mice were purchased from Charles River
Laboratories. Prdm1-EYFP, CD8 (E8I)-Cre, Tbx21F, EomesF, Cx3cr1CreER, and Rosa26LSL-

34

tdT

mice were originally obtained from The Jackson Laboratory. Bach2F mice are described

previously 15. All mice were housed in a specific pathogen-free facility at Washington University
in St. Louis and were used for infection at 8–12 wk of age, unless stated otherwise. All
experiments were performed according to a protocol approved by Washington University’s
Institutional Animal Care and Use Committee. Stocks of lymphocytic choriomeningitis virus
(LCMV) were made by propagating virus by infection of BHK21 cells, followed by
determination of titer in culture supernatants by plaque assay on Vero cells. For LCMV
infection, mice were infected with 2 × 105 PFUs of LCMV-Armstrong (LCMV-Arm) via the i.p.
route or 2 × 106 PFU of LCMV-clone 13 (LCMV-c13) by i.v. injection. For the quantification of
plasma viral load, RNA was extracted from 10 μl of plasma using TRIzol (Thermo
Fisher Scientific). Before RNA extraction, a spike-in of exogenous control External RNA
Controls Consortium RNA (Thermo Fisher Scientific) was carried out and used to normalize
viral loads following quantitative PCR as described previously 16, 17.
Bulk RNA-seq
Polyclonal PD-1+ CD8 T cells, which are enriched for LCMV-Ag–specific CD8 T cells,
were purified and sorted based on the indicated cell surface markers on 16 d after infection (dpi)
of LCMV-c13 from Prdm1-YFP mice as described previously 6, 18. Briefly, CD8+ T cells were
first enriched from splenocytes using the Dynabeads FlowComp Mouse CD8 T Cell Kit (Thermo
Fisher Scientific) followed by surface staining. We then sorted Prdm1EYFP−TIM3−CX3CR1− cells, which corresponded to TCF-1hi CD8 TPEX cells, and
divided Prdm1-EYFP+ cells into TIM3−CX3CR1+, TIM3+CX3CR1+, and
TIM3+CX3CR1− populations. Total RNA was extracted from 20,000–50,000 sorted cells using
Direct-Zol Micro Kit (Zymo Research), according to the manufacturer’s instructions. cDNA
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synthesis and amplification were performed with Next Ultra RNA Library Preparation Kit (New
England BioLabs). Libraries were sequenced on a HiSeq 3000 (Illumina) in single-read mode,
with a read length of 50 nucleotides producing ∼25 million reads per sample. Sequencing reads
were mapped to the National Center for Biotechnology Information mm9 mouse genome
assembly using STAR with default parameters, and mapping rates were higher than 90%.
Transcripts with 4 TPM in at least one sample were initially filtered, followed by principal
component analysis (PCA), unsupervised clustering, and profiling of subpopulation-specific
gene expression using Phantasus and limma packages
(V.15.1, https://artyomovlab.wustl.edu/phantasus/). The raw data have been deposited to
National Center for Biotechnology Information Gene Expression Omnibus.
scRNA-seq
scRNA-seq libraries were prepared using the 10× Single-Cell Immune Profiling Solution
Kit (v1 Chemistry), according to the manufacturer’s instructions. Briefly, FACS-sorted cells
were washed once with PBS + 0.04% BSA. Following reverse transcription and cell barcoding in
droplets, emulsions were broken and cDNA purified using Dynabeads MyOne SILANE,
followed by PCR amplification (98°C for 45 s; 14 cycles of 98°C for 20 s, 67°C for 30 s, and
72°C for 1 min; and 72°C for 1 min). For gene expression library construction, 50 ng of
amplified cDNA was fragmented and end-repaired, double-sided size selected with SPRIselect
beads, PCR amplified with sample indexing primers (98°C for 45 s; 14 cycles of 98°C for 20 s,
54°C for 30 s, and 72°C for 20 s; and 72°C for 1 min), and double-sided size selected with
SPRIselect beads. The prepared single-cell RNA libraries were sequenced on an Illumina HiSeq
4000 to a minimum sequencing depth of 25,000 reads/cell using the read lengths 28 bp read1, 8
bp i7 index, and 91 bp read2. Reads were aligned to the mm10 reference genome and quantified
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using cellranger count (10× Genomics, version 3.1.0). Filtered gene-barcodes matrices
containing only barcodes with unique molecular identifier counts passing the threshold for cell
detection were used for further analysis.
Additional analysis was performed using Seurat (version 3.1.2) 19. Cells with less than
200 genes detected or greater than 5% mitochondrial RNA content were excluded from analysis.
For clustering, raw unique molecular identifier counts were log normalized and variable genes
identified based on a variance stabilizing transformation. We assigned scores for S and G2/M
cell cycle phase based on previously defined gene sets 20 using the CellCycleScoring function.
Scaled z-scores for each gene were calculated using the ScaleData function and regressed against
the S-phase score and G2/M-phase score to reduce clustering based on cell cycle. Scaled z-scores
for variable genes were used as input into PCA. Clusters were identified using shared nearest
neighbor–based clustering based on the first 10 principal components with k = 15 and resolution
= 0.23. The same principal components were used to generate the Uniform Manifold
Approximation and Projection (UMAP) projections (Refs. 21 and L. McInnes, J. Healy, and J.
Melville, manuscript posted on arXiv, DOI: arXiv:1802.03426), which were generated with a
minimum distance of 0.1 and 30 neighbors. Expression of selected genes was plotted using lognormalized gene expression values.
Pseudotime and diffusion map analysis of scRNA-seq data were performed using Destiny
(version 3.2.0) 22. The normalized, log-transformed transcript count matrix was used to create a
diffusion map using the DiffusionMap function with default parameters. Cells were plotted using
the first three components of the diffusion map. A randomly selected cell from the TCF1+ cluster was used as the root cell for diffusion psuedotime computation using the DPT function
with default parameters.
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Treatments
For depletion of CD4 T cells, 200 μg of anti-CD4 (GK1.5, Leinco Technologies) was
injected on −1 and +1 dpi. For administration of tamoxifen (TAM, Sigma), 10 mg/ml solutions
were prepared in Corn oil (Sigma) and 1 mg gavaged orally.
Cell preparation, cell staining, and flow cytometry
Single-cell suspensions of splenocytes were prepared by manual disruption with frosted
glass slides. Lungs were minced with scissors and digested with Collagenase D (Sigma) and
DNase I (Sigma) with agitation for 1 h at 37°C followed by enrichment of lymphocytes by a
40/70 Percoll gradient. Absolute live cell counts were determined by trypan blue exclusion using
Vi-CELL (Beckman Coulter). Tetramer staining was performed using iTag-PE and
allophycocyanin LCMV gp33-41 and gp276-286 (MBL International). The following
monoclonal Abs were purchased from BioLegend, unless otherwise indicated: FITC-conjugated
anti-CD45.2 (104), PerCP-Cy5.5–conjugated anti-CD8β (YTS156.7), anti-CD4 (GK1.5), anti–
Ki-67 (16A8), PerCP-eFluor 710–conjugated anti-Eomes (eBioscience, Dan11mag),
allophycocyanin-conjugated CD366 (TIM-3, RMT3-23), anti–TNF-α (MP6-XT22), anti–
granzyme B (GZMB) (QA16A02), anti–T-bet (4B10), anti-CX3CR1 (SA011F11), Alexa Fluor
700–conjugated anti-CD44 (IM7), anti-CD45.2 (104), Brilliant Violet (BV) 421–conjugated antiTIM3 (RMT3-23), BV605-conjugated CD4 (GK1.5), anti-CD45.1 (A20), anti-CX3CR1
(SA011F11), BV711-conjugated anti-CD4 (RM4-5), PE-conjugated anti–IFN-γ (XMG1.2), anti–
PE-Cy7–conjugated anti–PD-1 (29F.1A12), PE-Dazzle 594–conjugated anti-B220 (RA3-6B2),
BUV395-conjugated anti-CD8 (53-6.7, Becton Dickinson), and anti–TCF-1 Ab (Cell Signaling
Technology, C63D9) and detected by Alexa Fluor 488–conjugated donkey anti-rabbit polyclonal
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IgG (Thermo Fisher Scientific, catalog no. R37118). Staining for transcription factors was
performed using the Foxp3 staining kit (eBioscience), according to the manufacturer’s
instructions.
For intracellular cytokine staining, splenocytes were cultured in RPMI-1640
supplemented with 10% FBS in the presence of 1 ug/ml of LCMV-gp33-41 peptide (GenScript
Biotech) and 5 ug/ml of brefeldin A (BioLegend) for 4 h. Cells were stained for surface makers
and then subject to LIVE/DEAD Aqua staining (Thermo Fisher Scientific) for 30 min at 4°C
before being fixed with 4% paraformaldehyde for 10 min at room temperature. Cells were then
washed twice with 0.03% saponin in 2% FBS/PBS before being stained with the indicated Abs in
0.3% saponin in 2% FBS/PBS for 20 min at 4°C.
BrdU incorporation assay was performed using the allophycocyanin BrdU Flow Kit (BD
Biosciences), according to the manufacturer’s instruction with one-time i.p. injection of 1 mg of
BrdU followed by tissue collection after 12 h.
Stained samples were analyzed with BD FACS LSR Fortessa, X20, or Symphony A3 or
sorted on Aria II or III. Data were processed with FlowJo Software (FlowJo).
Infection-matched adoptive transfer
SLAMF6+, SLAMF6−TIM3−CX3CR1+, or SLAMF6−TIM3+CX3CR1+PD-1+ CD8 T cells
were sorted from C57BL/6 mice on 21 dpi with LCMV-c13, and 3 × 105 CFSE-labeled cells
were i.v. transferred into infection-matched CD45.1 congenic recipients. Splenocytes from the
recipient mice were harvested 14 d after transfer, and donor-derived CD8 T cells were analyzed
by flow cytometry following magnetic bead–enrichment with a MojoSort Mouse CD8 T Cell
Isolation Kit (BioLegend).
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For transfer of memory CD8 T cells, CD44+CX3CR1+ or CD44+CX3CR1− CD8 T cells
were sorted from the spleen of mice that had been infected with LCMV-c13 >120 d prior. The
sort-purified memory CD8 T cells that contained 2,000–20,000 gp33-tetramer+ CD8 T cells were
transferred to uninfected CD45.1 congenic recipients and infected the next day. We quantitated
donor-derived CD8 T cells in the recipients without LCMV-Arm infection 24 h after transfer,
and donor cell expansion was calculated by dividing the donor cell number in infected recipients
on 6 dpi by that in uninfected control gp33-tetramer+ CD8 T cells.
Statistical analysis
The p values were calculated with an unpaired two-tailed Student t test or Mann–
Whitney U test for two-group comparisons and by one-way ANOVA for multigroup
comparisons with the Tukey post hoc test using Prism 8 software: *p < 0.05, **p < 0.01, ***p <
0.001, and ****p < 0.0001.
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Figure 1. CX3CR1 marks two distinct subsets of exhausted T cells.
(A) UMAP analysis of scRNA-seq data of 2141 gp-33 specific CD8 T cells on 21 dpi with
LCMV-c13. Right panels show the expression of the indicated genes. (B and C) Flow
cytometry showing expression of TIM3, TCF-1, CX3CR1, and CD44 in LCMV gp33-specific
CD8 T cells 4 wk after infection of C57BL/6 mice with LCMV-c13. Numbers indicate
percentages of gated cells in each parental population shown in the figure. Data are representative
of >5 independent experiments with >20 mice in total. (D) Expression of PD-1 measured by flow
cytometry in the indicated population of LCMV-gp33-specific CD8 T cells on 22 dpi,
quantified in the right panel. Data are representative of three independent experiments with n 5
3 mice each. (E) GZMB expression ex vivo as measured by flow cytometry of LCMV gp33specific CD8 T cells in the indicated subpopulations on 22 dpi with LCMV-c13. Data are
representative of two independent experiments with n = 4-6 mice each. (F) BrdU incorporation
as measured by flow cytometry of LCMV gp33-specific CD8 T cells in the indicated
subpopulations on 22 dpi with LCMV-c13 12 h after i.p. administration of 1 mg BrdU. Data are
representative of three independent experiments with n 5 3 mice each. *p < 0.05, **p < 0.01,
****p < 0.0001
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Figure 2. Characterization of CX3CR1 expressing CD8 T cells in infection.
(A) UMAP plots of scRNA-seq data of LCMV-gp33-specific CD8 T cells in C57BL/6 mice on 21
dpi withLCMV-c13 showing expression of indicated genes. (B) Flow cytometry showing gating
strategy for analysis of exhausted CD8 T cell subsets showing expression of CD44, TIM3,
CX3CR1, and TCF-1 byLCMV gp33-specific cells on Day 22 after LCMV-c13 infection. Data
are representative of greater than10 independent experiments. (C) Expression of Ki-67 in
subpopulations of gp33-specific CD8 T cells defined by TIM3 and CX3CR1 in LCMV-c13infected C57BL/6 mice at different time points after infection. Data are representative of two
experiments with n = 5 mice for each. (D) Flow cytometry showing expression of Nur77 in
indicated subset of gp33 specific CD8 T cells 8dpi with LCMV-c13. Data in right panel are
representative of two independent experiments with n = 3 mice each. (E) Flow cytometry
analyzing expression of TIM3, CX3CR1, and TCF-1 by LCMV gp33-specific CD8 T cells in
lungs of C57BL/6 mice that were intravenously injected with 3 ug of anti-CD45.2 three minutes
before euthanasia. Data are representative of 2 independent experiments with n=3 mice each.
Each dot in the graphs indicates an individual mouse that was examined, and data are shown by
mean± SD. Statistical differences were tested using one-way ANOVA with a Tukey post-hoc test
(B) and student’s t-test (C).
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Figure 3. Development and dynamics of CX3CR1 positive subsets of exhausted CD8 T cells.
(A-C) Flow Cytometry showing expression of CX3CR1 and TIM3 (A) in TCF-1lo/– gp33specific CD8 T cells in control and CD4 T cell-depleted mice on the indicated dpi with LCMVc13. Pooled data from two independent experiments with n=4-5 mice in total per group.
Statistical analyses are shown in (B) and (C) as mean ± SD. (D) Flow cytometry plots showing
H-2Db(gp33-41) binding CD8 T cells and expression of TCF-1, CX3CR1, and TIM3 on 30 dpi in
mice treated with PBS or anti-PD-L1 initiated on22 dpi. (E) Frequencies and absolute numbers of
indicated populations from (D) shown as mean ± SD. Data are pooled from two independent
experiments with n=5-6 mice per group in total.
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Figure 4. TIM3−CX3CR1+ cells are progenitor-like cells upstream of TIM3+CX3CR1+
proliferating effector CD8 T cells.
(A) PCA plot derived from population-level RNA-seq analysis of the indicated subpopulations of
PD-1+ CD8 T cells on 16 dpi. The populations were defined using Prdm1-YFP mice as Prdm1YFP− (TCF-1hi) and subpopulations of Prdm1-YFP+ (TCF-1lo/−) with a combination of CX3CR1
and TIM3. (B) Heat map showing expression of the indicated genes by the indicated subsets of
PD-1+ CD8 T cells. Expression values were averaged from three independent samples for each
population and color-coded based on row mean and fold changes. (C) Flow cytometry plots
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showing expression of TCF-1 in the indicated subsets of H-2Db (gp33–41) + CD8 T cells 22 dpi
LCMV-c13 infection. Data in the right panel are representative of two independent experiments
with n = 3–4 mice each. (D) Experimental schematic of infection-matched adoptive transfer. (E–
G) Flow cytometry showing expression of SLAMF6, CX3CR1, and TIM3 in sorted donor
CD45.2+PD-1+ CD8 T cells prior to transfer (top) and of the donor-derived (CD45.2) PD-1+ CD8
T cells 14 d after transfer. Frequencies of cells in each population and total cell yield from each
donor population were quantified in (E) and (F). (H) CFSE dilution and expression of TIM3 of
donor cells derived from TIM3−CX3CR1+ cells. Expression of TIM3 in CFSElo, CFSEmed, and
CFSEhi subpopulations is shown by a histogram overlay and geographical mean fluorescence
intensity (gMFI). (I) Pseudotime and diffusion map analysis of scRNA-seq data from (Fig. 1A
performed using destiny package.
Data shown in (D–G) are pooled from two independent experiments with n = 4–6 mice recipient
mice analyzed for each donor transfer and shown as shown as mean ± SD. Statistical analysis by
one-way ANOVA was performed on data in (G). *p < 0.05, **p < 0.01, ***p < 0.001, ****p <
0.0001.
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Figure 5. Profiling of differentially expressed genes between distinct subpopulations of PD1+ CD8 T cells following LCMV-c13 infection by bulk RNA-seq.
(A) Heatmap showing K-mean clustering of genes differentially expressed between distinct
subpopulations on 16 dpi. Gene expression levels are shown as z-score normalized to each row
mean.
(B) Gene Set Enrichment Analysis (GSEA) showing pathways associated with genes that were
differentially expressed between TIM3– CX3CR1+ and TIM3+ CX3CR1+ populations.
(C) Heat maps showing expression of indicated genes by distinct subsets of PD-1+ CD8 T cells.
Expression values were averaged from three independent samples for each population and colorcodedbased on row mean and fold-changes.
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Figure 6. T-bet is critical for the maintenance of CX3CR1+ exhausted CD8 T cell
populations.
(A) Flow cytometry plots showing the expression of the indicated molecules within total and Tbethi gp33-specific CD8 T cells 22 dpi LCMV-c13 infection. Data are representative of three
independent experiments with n = 4-6 mice each. (B) Flow cytometry plots showing
expression of T-bet and Eomes in the indicated subsets of gp33-specific CD8 T cells in the
spleen on 22 dpi with LCMV-c13 infection. Data are representative of three independent
experiments with n 5 5 mice each. (C-E) Flow cytometry showing expression of TCF-1,
CX3CR1, and TIM3 by gp33-specific CD8 T cells in control Tbx21F/F and CD8-cre Tbx21 F/F
mice on 29 dpi with LCMV-c13. Representative flow cytometry plots are shown in (C) with the
frequencies of gated cells in each parental population, and statistical analyses are shown in (D)
and (E). Data are shown as mean ± SD and are pooled from three independent experiments with n
> 8 mice per genotype. Dots in the graphs in (A), (C), and (D) indicate individual mice. Data in
(A), (C), and (D) are shown as mean ± SD. Statistical differences in (A) were tested using oneway ANOVA with a Tukey post hoc test. For (C), Student t test was used. For (D), MannWhitney U test was used. (F) LCMV-glycoprotein mRNA abundance in plasma as assessed by
quantitative RT-PCR in Tbx21F/F and CD8-cre Tbx21F/F mice on 100 dpi with LCMV-c13. Data
are pooled from two independent experiments with n = 4 (Tbx21F/F) and n=5 (CD8-cre+
Tbx21F/F) mice per genotype in total. Horizontal bars indicate median for samples in each
genotype, and the statistical differences were assessed by Mann-Whitney U test. The dotted line
indicates the limit of detection. *p < 0.05, **p < 0.01, ****p < 0.0001.
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Figure 7. Characterization of CD8 T cell-specific Tbx21- and Eomes- deficient mice during
chronic infection.
(A-B, E-F) Flow cytometry plots showing expression of IFN-γ and TNF-α in CD8 T cells
following ex vivo peptide re-stimulation of splenocytes from Tbx21F/F and CD8-cre Tbx21F/F (AB), and EomesF/F and CD8-cre EomesF/F (E-F) on 30 dpi of LCMV-c13 infection. Statistical
analysis is shown in (B) and (F). (C-D, G-H) Flow cytometry showing expression of Granzyme
B by intracellular staining in the indicated subsets of gp33-specific CD8 T cells from Tbx21F/F and
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CD8-cre Tbx21F/F (C-D) and EomesF/F and CD8- cre EomesF/F (G-H). Data in (B, D, F, and H) are
shown as mean ± SD and are representative data from 2-3 independent experiments with n=4-5
mice analyzed per genotype; unpaired student’s t-test was used for statistical analysis. (I) Viral
abundance as assessed by qRT-PCR in plasma from EomesF/F and CD8-cre EomesF/F mice on
100 dpi with LCMV-c13. Data are pooled from 3 independent experiments with n=7 (EomesF/F)
and n=9 (CD8-cre EomesF/F) in total. The horizontal line indicates median and statistical analysis
was performed using Mann-Whitney U-test. The dotted line indicates the limit of detection.
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Figure 8. Opposing roles of EOMES and BACH2 in the differentiation of progenitor-like
subsets of exhausted CD8 T cells.
(A-C) Flow cytometry showing expression of CD44, TCF-1, CX3CR1, and TIM3 of gp33tetramer+ CD8 T cells in the spleen of control EomesF/F and CD8-cre EomesF/F mice on 28 dpi
with LCMV-c13. Representative flow cytometry plots are shown in (A) with the frequencies of
gated cells in each parental population, and statistical analyses are shown in (B) and (C). Data are
representative of three independent experiments with n = 4-6 mice per genotype in each
experiment. (D-G) Flow cytometry showing the expression of TCF-1, CX3CR1, and TIM3 of
gp33-tetramer+ CD8 T cells in Bach2F/F and CD8-Cre+Bach2F/F mice 30 d after LCMV-c13
infection. Representative flow cytometry plots are shown in (D) with frequencies of gated cells in
each parental population, and statistical analyses are shown in (E)-(G). Data are pooled from two
independent experiments with n = 4 (Bach2F/F) and n = 5 (CD8-Cre+Bach2F/F) in total. All
statistical analysis plots are shown as mean ± SD with statistics performed using an unpaired t
test. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 9. Lineage tracing reveals the stability and persistence of CX3CR1+PD-1+ CD8 T
cells.
(A) Experimental schematic of TAM administration to Cx3cr1creERT2/+ R26tdT mice infected with
LCMV-c13 and analysis. (B) Flow cytometry plots showing the expression of tdT and TCF-1 in
gp33-specific CD8 T cells 16 h following TAM administration on 8 dpi. Data from replicates
are shown in the right panel. Data are representative of two independent experiments with n =
3-4 mice each. A paired t test for the statistical analysis. (C) Representative flow cytometry
plots showing expression of tdT and CX3CR1 in PD-1+ CD8 T cells in PBMCs and
frequencies of tdT+ cells within CX3CR1+PD-1+ CD8 T cells in the PBMC in Cx3cr1CreER/+
R26tdT mice at the indicated time points after infection and TAM administration. Data are
representative of two independent experiments with n=3 mice each. (D) Flow cytometry plots
showing expression of the tdT reporter in each of gp33-specific CD8 T cell subpopulations in the
spleen of Cx3cr1creERT2/+ R26tdT mice on 22 dpi. Data are representative of two independent
experiments with n = 3 mice each. **p < 0.01, ***p < 0.001.
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Figure 10. CX3CR1+ CD8 T cells during the chronic phase give rise to TCF-1+ chronic
memory cells following the resolution of viremia.
(A and B) Flow cytometry plots showing expression of tdTomato (tdT), TCF-1, CX3CR1,
and TIM3 in gp33-specific CD8 T cells in the splenocytes of LCMV- c13-infected
Cx3cr1creERT2/+ R26tdT mice treated with TAM on 28 dpi and analyzed on >120 dpi.
Representative data from two independent experiments with n = 3 mice are shown. Flow plots
are shown in (A), and replicates from one experiment are shown as mean ± SD. (B). (C)
Expression of IFN-γ and TNF-α in the indicated subsets of CD8 T cells in the spleen of 29 dpi
LCMV-c13-infected mice, >120 dpi LCMV-Arm-infected mice, or >120 dpi LCMV-c13infected mice following stimulation with LCMV-gp33 peptide ex vivo for 4 h. Data are
representative of two independent experiments with n =3 mice each. (D) Expression of TCF-1
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and CX3CR1 in LCMV-gp33-specific splenic CD8 T cells (top) and expression of PD-1 and
TOX in TCF-1+ LCMV-gp33-specific CD8 T cells at the indicated time point after LCMV-Arm
or LCMV-c13 infection. Frequencies of TOX+ cells and levels of TOX expression are shown
with mean ± SD. (E) Schematic of adoptive transfer experiment to assess the capability of
secondary expansion of CX3CR1+ and CX3CR1– CD8 T cells that were sorted from LCMVArm- and LCMV-c13-infected mice. The right panel shows data from replicates. Data are
representative of two independent experiments with n = 2 donor mice and n= 5 recipient mice per
experiment. Fold expansion was calculated by fold change of gp33-specific CD8 T cells
followed by normalization to no infection control.
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Chapter 3: BCL6-dependent TCF-1+ progenitor cells
maintain effector and helper CD4 T cell responses to
persistent antigen

The contents of this chapter are from a paper that is accepted at Immunity
Xia, Y.*, Sandor, K. S.*, Pai, J. A.*, Daniel, B., Raju, S., Wu, R., Hsiung, S., Qi, Y., Yangdon,
T., Okamoto, M., Chou, C., Hiam-Galvez, K. J., Schreiber, R. D., Murphy, K. M., Satpathy,
A. T., & Egawa, T. (2022). BCL6-dependent TCF-1+ progenitor cells maintain effector and
helper CD4 T cell responses to persistent antigen. [Accepted].
Submitted as a preprint. doi.org/10.1101/2021.08.06.455141. (*: equal contribution).

3.1 Abstract
Shortly after priming, the fate of activated CD4 T cells is segregated into BCL6+
follicular helper T (Tfh) and BCL6– effector (Teff) cells. However, it remains unknown how
these subsets are sustained in the presence of chronic antigen stimulation. Using a combination
of single cell- and population-based approaches, we show that in chronic viral infection,
activated CD4 T cells differentiate in a BCL6-dependent manner into TCF-1+ progenitor cells
with superior capacity to expand and give rise to both Teff and Tfh . They share properties with
progenitor-exhausted CD8 T cells and are required for the continued generation of antigenspecific CD4 T cells as antigen persists. In response to tumors, an analogous CD4 T cell
population develops in draining lymph nodes. Our study reveals the heterogeneity and plasticity
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of CD4 T cells upon encountering persistent antigen and highlights their population dynamics
through a stable, bipotent, intermediate state.

3.2 Introduction
CD4 T cells play a central role in coordinating innate and adaptive immunity. In response
to signals through T cell receptors (TCR) and cytokines provided by dendritic cells, they
functionally differentiate into T effector (Teff) cells and produce context-specific cytokines to
coordinate activation of innate immune cells

1–3

. Activated CD4 T cells also differentiate into

follicular helper T (Tfh) cells that provide contact-dependent help to B cells for their expansion
and affinity maturation. Shortly after priming, CD4 T cells diverge into BCL6– and BCL6+
subsets depending on the strength of TCR and IL-2R signaling in a B cell-independent manner 4–
7

. Stronger TCR signaling and subsequent upregulation of IL-2 is associated with the expression

of BCL6 and differentiation into Tfh cells, whereas activation of IL-2R signaling and IL-12R
signaling induces upregulation of the transcription factor Blimp1 (PRDM1), which promotes
Teff differentiation and suppresses Tfh fate via downregulation of BCL6 and TCF-14,8–10. In
studies using acute pathogen infection or non-replicating antigen, the early binary fate decision
of CD4 T cells is stable as early BCL6+ cells exhibit skewed developmental potential towards
Tfh at the expense of Teff cells 4,11.
Following antigen clearance, the antigen-specific CD4 T cell population contracts, giving
rise to memory CD4 T cells that confer long-lasting protection against re-infection. These cells
are classified into central (Tcm) and effector (Tem) memory subpopulations

12

. Tem cells,

similar to Teff cells, express tissue homing receptors, promptly produce effector cytokines such
as interferon-gamma (IFN-g) upon rechallenge, and decay faster than Tcm. In contrast, Tcm cells
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express homing receptors, such as CCR7 and CD62L, that facilitate their homing to lymphoid
organs. Additionally, Tcm cells are capable of robust IL-2 production immediately after
stimulation, resembling BCL6+ T helper cells that emerge early after priming. In acute viral or
intracellular bacterial infections, Tcm cells are derived from central memory precursor CD4 T
cells (Tcmp) that are formed at the peak of the T cell response 3,13,14. Tcmp cells already express
Tcm-related genes such as Tcf7, Ccr7, Id3 and Bcl2, but phenotypically overlap with pre-Tfh
cells with an intermediate level of BCL6 and CXCR5 expression

15,16

. Thus, the relationship

between Tfh and memory populations and the nature of memory precursor cells has remained
incompletely understood.
CD4 T cells also play essential roles in controlling chronic viral infection and tumors, in
which their responses must be sustained for substantially longer periods, compared to acute
infection or vaccine-elicited immune responses. Similar to CD8 T cells, activated CD4 T cells
acquire distinct phenotypes in the presence of chronic antigen compared to acute viral infection
17–19

. Whereas increased expression of inhibitory receptors is the hallmark feature of exhausted

CD8 T cells, CD4 T cells exposed to persistent antigen exhibit a unique pattern of gene
expression changes, including elevated expression of Bcl6 and additional similarities to Tfh cells
20

, while expression of multiple inhibitory receptors is less pronounced compared to CD8 T cells

17

. In CD8 T cells, a series of recent studies identified a subset of stem-like or progenitor-like

exhausted CD8 T cells, referred to as T progenitor exhausted (TPEX) cells, that express the
transcription factors (TF) TCF-1 and BCL6, and the canonical Tfh marker CXCR5

21–25

. TPEX

cells are necessary to sustain CD8 T cell effector responses and critical for enhanced antiviral
and anti-tumor immunity in response to immune checkpoint blockade (ICB). Given the
terminally differentiated nature of CD4 Teff and Tfh cells, the continued CD4 T cell response by
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Teff and Tfh cells may similarly be supported by their continued differentiation from less
differentiated stem-like, or progenitor cells, which could be similar to previously proposed TCF1+ cells generated by asymmetric divisions 26. However, it remains unknown whether sustained
CD4 T cell response depends on such a progenitor population, or how they are distinct, if any,
from pre-Tfh or memory CD4 T cells.
To address this question, we performed an unbiased characterization of the heterogeneity
of antigen-specific CD4 T cells in response to infection with a chronic strain of Lymphocytic
choriomeningitis virus (LCMV, clone 13 (c13)), which achieves prolonged antigen persistence,
infection and identified a population of PD-1+ progenitor CD4 T (Tprog) cells that were TCF-1+
BCL6lo/– and distinct from TCF-1– BCL6– Teff and TCF-1+ BCL6hi Tfh cells. This cell
population is detectable at the peak of T cell response and persists into the chronic phase of
infection in a B cell-independent manner. Trajectory analysis, TCR clonal tracing, and adoptive
transfer experiments demonstrate that they serve as common progenitors for both Teff and Tfh
cells. Epigenomic analysis with single-cell ATAC-seq (scATAC-seq) suggests that TCF-1+
BCL6lo/– progenitor cells require NFAT and AP-1 TF activity for early differentiation, followed
by bifurcation to the two distinct terminal fates. Their development also requires BCL6 and CD4
T cell-specific conditional deletion of Bcl6 not only results in the expected loss of BCL6hi TCF1+ Tfh but also the total ablation of TCF-1– BCL6– Teff cells two weeks after infection, despite
an intact initial expansion. Finally, in tumor-bearing mice, phenotypes of tumor-reactive CD4 T
cells were distinct between the tumor microenvironment and tumor-draining lymph nodes
(tdLNs). An analogous heterogeneity of CD4 T cells was observed in tdLNs, while antigenspecific CD4 T cells in the tumor were predominantly TCF-1– Teff cells, suggesting tumorspecific CD4 T cells are maintained in secondary lymphoid organs rather than in the tumor
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microenvironment. These results collectively indicate that following an initial wave of naive T
cell-derived differentiation of Teff and Tfh cells, CD4 Teff and Tfh cell responses to persistent
antigen are maintained by a pool of BCL6-dependent TCF-1+ common Tprog cells, akin to how
the CD8 response is maintained by CD8 TPEX.

3.3 Results
scRNA-seq and flow cytometry reveals heterogeneity within antigen-specific CD4 T cells
responding to chronic viral infection.
To obtain an unbiased overview of the CD4 T cell response to persisting antigen, we
performed paired single-cell RNA-seq (scRNA-seq) and TCR sequencing of I-Ab-LCMV-gp66specific (Tet+) and the remaining total CD4 T cells (Tet–) in C57BL/6 (B6) mice infected either
with LCMV-c13 (collected 8 or 21 days post infection - dpi) or with an acute strain of LCMV
(Armstrong strain (Arm)) (collected 8 or 21 dpi) (Fig. 11A). In total, we obtained 80,785 cells
after quality control filtering based on the number of genes captured and percent mitochondrial
reads per cell (# of genes within 2 standard deviations of mean; % mitochondrial reads < 95thpercentile; Methods), and we obtained paired TCRαβ sequences in 89.0% of these cells (Fig.
11B). Dimensionality reduction and clustering of the cells based on their gene expression
profiles identified 15 cell type clusters, most of which were grouped into 5 large clusters: Sell+
Ccr7+ Tcf7+ Slamf6– naive (Cluster 1 from RNA-seq as abbreviated as C1r), Tcf7+ Slamf6+ Bcl6–
Cxcr5lo/– resting memory-like (C2r), Tcf7+ Slamf6+ activated memory-like (C3r and 4r), Tcf7+
Slamf6+ Bcl6+ Cxcr5+ Tfh (C5r), and Prdm1+ Slamf1+ Cxcr6+ Teff cells (C6r and C7r) (Fig. 12A,
B; Fig. 11C). C3r and C4r were characterized by the expression of Tcf7, Slamf6, Pdcd1, Zbtb32,
and Bcl2 at similar levels to C2r, and additionally expressed Cd69 and Mif, which are
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upregulated by activated T cells

27,28

. They also expressed additional genes induced by TCR

signaling, including Egr1, Egr2, Nr4a1, Tnfrsf4, Nfkbia and Batf (Fig. 12A-C; Fig. 13A, B),
suggesting that they represent activated memory-like cells. We also identified 3 clusters of
regulatory T cells (Tregs), including thymic Il2rahi and peripheral Il2ralo Tregs (C8r and C9r,
respectively), as well as a population of proliferating Tregs (C10r). C11r comprised CD4 T cells
expressing high levels of genes related to the IFN response, including Irf7 and IFN-stimulated
genes Isg15, Ifit1, and Ifit3. Lastly, we found several additional small clusters, including an
undefined population of non-Treg CD4 T cells with elevated expression of the chemokine
receptors, Ccr4 and Ccr6 (C12r), Myb (C13r), Gzmk (C14r), and proliferating markers including
Hmgb2 and Stmn1 (C15r).
Arm-8 dpi Tet– cells, which contained a mixture of bystander naive cells, resting memory
CD4 T cells, and LCMV-reactive CD4 T cells recognizing non-dominant epitopes, were present
in all 5 major clusters, with a substantial proportion (~30%) in the C1r Naive cluster (Fig. 12A).
In contrast, Tet+ cells more frequently exhibited Teff and Tfh phenotypes, constituting
approximately 40% of the whole population. A large proportion of the remaining Tet+ cells
displayed the resting memory phenotype (Fig. 12A), likely corresponding to Tcmp

13,14

. In c13

infection at 8 and 21 dpi, the relative frequency of Teff cells in Tet– CD4 T cells was reduced
compared to CD4 T cells responding to Arm infection, while that of Tfh cells was similar,
indicating Tfh-skewing of expanding CD4 T cells (Fig. 12A). As in Arm infection, Teff cells
were enriched in Tet+ cells compared to Tet– cells in c13 infection. However, compared to Tet+
cells in Arm infection, the percentage of Teff cells within Tet+ cells in c13 infection was notably
reduced on 8 dpi (Fig. 12A). Frequencies of Tet+ cells with the resting memory phenotype (C2r)
were decreased in c13 infection compared to Arm infection on 8 and 21 dpi. However, c13-Tet+
66

cells in this cluster differed qualitatively from their Arm counterparts with a relative upregulation
of activation-induced genes (e.g., Pdcd1, Lag3, Tnfrsf4) and IFN-I-induced genes (e.g., Ifi27l2a),
which are associated with Tfh cells14, and downregulation of the Th1/Teff-associated genes,
Ccl5, Nkg7 and Ly6c23,29,30(Fig. 12C, right and Fig. 13C, D). These changes in gene expression
suggest that cells in the memory-like cell populations may be biased towards Tfh over Teff. In
addition, activated memory-like cells in C3r and C4r were significantly increased in c13-Tet+
samples compared to Arm infection samples on 21 dpi (Fig. 12A and Fig. 13E). Altogether,
these results suggest the presence of a distinct Tcf7+ resting memory population (C2r) in c13
infection and increased mobilization to the activated memory-like cell pool (C3/4r) and into
more differentiated cells.
To validate the scRNA-seq dataset with analysis of the subset-specific proteins, we used
flow cytometry to analyze splenocytes of c13-infected B6 mice for BCL6 and TCF-1 expression
(Fig. 12D-F). On 5 dpi, TCF-1+ cells uniformly upregulated BCL6, which is gradually and
uniformly downregulated on 8 and 15 dpi (Fig. 12D). On 22 dpi, TCF-1+ cells constituted a
large proportion of Tet+ CD4 T cells (Fig. 12E, F). and a subfraction of these cells expressed
higher BCL6 as they further underwent differentiation into Tfh cells and supported expansion of
germinal center (GC) B cells. A similar change was observed in expression of CXCR5 (Fig.
12E). Consistent with the scRNA-seq data, approximately 15% of Tet+ CD4 T cells expressed
CD69, and about half of them were TCF1+ BCL6lo/–. TCF-1– cells minimally expressed CD69
(Fig. 12G). Both TCF-1+ populations expressed Ly-108 (encoded by Slamf6) but lacked
expression of the Teff marker Prdm1 based on a Prdm1-YFP reporter (Fig. 12E, H). TCF-1+
BCL6lo/– cells expressed lower PD-1 and higher Ly-108 compared to TCF-1+ BCL6hi cells, and a
minority (~5%) of them expressed CCR7, in contrast to resting Tcm. TCF-1– cells upregulated
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T-bet, CXCR6 and CD150 (encoded by Slamf1) as well as the Prdm1 reporter, indicating that
they were highly enriched for differentiated Teff cells. TCF-1– cells also contained a small
percentage (~5%) of Foxp3+ Treg cells (Fig. 13F). Consistent with previous reports, CXCR5
was a reliable surrogate marker of BCL6, while Ly-108 was a reliable surrogate for TCF-1
expression (Figs. 12E and 13G). In terms of tissue distribution, Tfh cells were barely detected in
the bone marrow or liver, whereas Teff cells were detected at higher percentages (40-50%) in
those organs compared to the spleen, and TCF-1+ BCL6lo/– cells were also present in those
organs (Fig. 13H, I). While CD4 T cells from all three populations produced cytokines following
stimulation with gp61-77 peptide ex vivo, production of TNF and IL-2 was significantly reduced
in TCF-1– cells (Fig. 13J), suggesting that they are relatively exhausted compared to two other
populations of PD-1+ CD4 T cells.
To investigate the similarities between CD4 and CD8 T cells in c13 infection, we
compared the transcriptional profiles of each CD4 population to a single-cell CD8 T cell dataset
from LCMV-Arm and c13 infection

31

. We calculated gene signature scores of CD8 T cell

populations, including CD8 memory (Tmem), TPEX (Texprog), KLR-expressing effector cells
(TexKLR), intermediate/transitory cells (Texint), and terminally exhausted cells (Texterm)
(Methods). First, we observed that the CD4 Tcf7+ C2r population exhibited the highest similarity
to CD8 Tmem in acute infection (mean CD8 Tmem signature score: 0.231; Fig. 13), supporting
their similarity to resting memory CD8 T cells as observed by our scRNA-seq analysis. Second,
CD4 Teff cells aligned closely to the exhausted CD8 clusters TexKLR, Texint, and Texterm in
c13 infection, with the C7r Teff-Ifng cluster displaying the highest similarity to Texterm (mean
CD8 Texterm signature score: 0.295), in line with the elevated expression of exhaustion-related
markers (e.g. Havcr2, Lag3) in this cluster (Fig. 13B). Lastly, using the Texprog gene signature,
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which comprised 108 genes including Tcf7, Slamf6, and Id3, we observed that CD8 TPEX cells
were most transcriptionally similar to Tcf7+ Cd69+ Pdcd1+ CD4 T cells (mean CD8 TPEX
signature score: 0.354), and also showed similarity to Tfh cells (mean CD8 TPEX signature
score: 0.328; Fig 13K). In line with this similarity, the frequency of Tcf7+ Slamf6+ Bcl2+ Pdcd1+
memory-like cells was increased in c13 infection, compared to Arm infection (Fig 13E),
indicative of progenitor potential, which actively supports the maintenance of Teff and Tfh cells
in response to persistent antigen.
Collectively, our results indicate that with chronic persistence of antigen, a substantial
fraction of antigen-specific CD4 T cells acquire a TCF-1+ PD-1+ memory-like phenotype. These
memory-like CD4 T cells resemble CD8 TPEX and contain a subpopulation of cells with a gene
expression signature associated with TCR-mediated activation. They may thus act as progenitor
cells to support the maintenance of Teff and Tfh cells in response to persistent antigen.

Memory-like cells are enriched for common progenitors for both Tfh and Teff
To investigate the potential developmental relationships between CD4 T cell clusters,
including memory-like, Teff, and Tfh cells, we performed trajectory inference analysis (Monocle
3; Methods) using the scRNA-seq data. To specifically analyze the transition of cells in response
to chronic antigen stimulation, we reclustered Tet+ cells from c13 infection on 8 and 21 dpi and
labeled the cells according to the previously defined phenotypic clusters (Fig. 14A, 15A). Tfh
(C5r) and Teff (C6/7r) were mapped separately and most distantly in pseudotime from the naive
cluster (C1r), supporting their terminally differentiated states. Naive cells were closely projected
to the resting memory-like populations (C2r), but did not directly transition into either terminally
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differentiated population. Instead, cells in C2r transitioned into mature Tfh (C5r) or Teff (C6/7r)
cells after passing through the activated memory-like state (C3r) and a subsequent bifurcation,
suggesting that the memory-like state serves as a common progenitor for both Tfh and Teff fates.
Along the trajectory from naive to mature Tfh cells (Fig. 14B, top), Tcf7 expression remained
roughly constant across all differentiation time points (Fig. 14C). As cells differentiated from
C3/4r, Bcl6 and Cxcr5 expression was increased following commitment to the mature Tfh
phenotype (Fig. 14C). In contrast, Tcf7 expression decreased along the Teff trajectory (Fig. 14B,
bottom), while Runx3, Prdm1, and Ifng expression increased (Fig. 14D).
To further support our hypothesis that cells in the memory-like clusters constitute a
common progenitor pool for Tfh and Teff cells, we paired single-cell phenotyping with TCR
sequence information to define clonal developmental trajectories of memory-like (C2r and
C3/4r), Tfh (C5r), and Teff (C6/7r) cells. We defined TCR clones based on identical TCRαβ
CDR3 sequences and identified 10,330 total clones from c13 infection 21 dpi cells (Fig. 15B).
Most of the expanded clones (>1 cell per clone) in all infection conditions and timepoints were
observed in the Tet+ population, while the majority of Tet– clones were detected as unexpanded
singletons (Fig. 15C-D). Among expanded Tet+ clones on 21 dpi in LCMV-c13 (880 total
expanded clones; 9,803 total cells), 483 clones were found in two or more of the three broad
phenotypic clusters, and 442 of the 483 (819%) expanded clones were detected in the memorylike population, in addition to Tfh and/or Teff populations (Fig. 14E). Indeed, the most highly
expanded clones from c13-21 dpi all comprised cells with the memory-like phenotypes (Fig.
14F). In contrast, only 41 expanded clones (7.8%) were detected in both Tfh and Teff
populations, but not in the memory-like population (Fig. 14E). Taken together, these results
suggest that during LCMV-c13 infection, the vast majority of the long-term clonal CD4 T cell
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response is maintained by the memory-like cells that replace the initially expanded naive poolderived clones and function as putative common Tprog cells.

Epigenetic differentiation trajectories of progenitor CD4 T cells
To identify epigenetic pathways of TCF-1+ progenitor CD4 T cell differentiation, we
performed single-cell assay for transposase accessible chromatin with sequencing (scATAC-seq)
on PD-1+ CD4 T cells from the spleens of c13-infected mice on 21 dpi (Fig. 16A). In total, we
obtained high quality scATAC-seq profiles from 11,611 cells (unique fragment count >1,000,
transcription start site enrichment >11; Fig. 16B, C) and performed dimensionality reduction
using iterative latent semantic indexing followed by UMAP
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, which identified 8 distinct

chromatin state clusters after removing thymic Tregs (Fig. 14A). Next, we integrated scATACseq and scRNA-seq datasets to define the identity of each cell cluster, and link pseudo-scRNAseq expression values to each cell in the scATAC-seq data (Fig. 17B; Fig. 16D; scRNA-seq for
integration analyses generated from the same experiments, Methods). To perform integrative
analysis, we first visualized the accessibility of cell cluster marker genes identified in scRNA-seq
data shown in Fig. 12 by calculating gene scores, which is a measurement of the overall
accessibility of the gene body and surrounding open chromatin regions (OCR) 33; (see Methods).
Second, we performed unconstrained integration of single-cell transcriptomic and chromatin
accessibility profiles to calculate gene integration scores, yielding gene expression profiles at the
single-cell level in the scATAC-seq defined UMAP space (see Methods). Importantly, these
analyses identified cells with Tfh (C4a and C5a), progenitor (C6a and C7a) and Teff (C2a and
C3a) phenotypes; C6a and 7a were marked by intermediate accessibility of Tcf7 and Slamf6 and
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low to intermediate accessibility of Cxcr5 and Bcl6, corresponding to the putative Tprog cell
clusters identified in the transcriptomic analysis (Fig. 17C). Despite the overall epigenetic
similarity between C6a and C7a, hierarchical clustering of differentially activated loci revealed
increased accessibility in C6a at several loci related to T cell activation, including Cd69, Batf,
Nr4a2, Irf4, and Tox (Fig. 17C; Fig. 16E, F). The result suggests that C7a and C6a correspond
to the resting (C2r) and activated (C3r) Tprog cell clusters identified by scRNA-seq,
respectively. To further support these findings, we defined the differential OCRs for each cluster
and performed motif enrichment analysis between C6a and C7a, identifying several motifs
associated with NFAT and AP-1 TF families in C6a compared to C7a (Fig. 17D). In contrast,
Tfh cells showed high TF motif enrichment of TCF/LEF TF family members, while Teff cells
showed high enrichment of TBX and RUNX motifs (Fig. 17D).
To further investigate the epigenetic dynamics between the Tprog, Teff, and Tfh
populations, we constructed cellular trajectories for the transition to either terminally
differentiated CD4 subset, and analyzed differential TF motif accessibility along the two paths
(Fig. 17E, top). Tprog cells are clustered in between the Tfh and Teff cells, and TCR-based
analysis uncovered extensive clonal sharing of Teff and Tfh cells with this population (Figs. 12,
14). Therefore, we used Tprog cells as a starting point, and reconstructed two differentiation
trajectories using a nearest-neighbor approach (sequential selection of similar chromatin states
based on Euclidean distance, see Methods). As cells transitioned from C7a to C6a (representing
the common path of the two trajectories), they gained accessibility at NFAT, BACH, and
BATF/AP-1 motifs, representing the early chromatin remodeling events of Tprog commitment
(Fig. 17E). After this common differentiation step, cells bifurcated into terminally differentiated
Teff and Tfh phenotypes. At these later stages of the trajectory, cells lost accessibility at
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common progenitor TF motifs and gained accessibility at Tfh- (e.g., TCF7 , ASCL, CEBP, and
MAF) 9,34–36, and Teff-related TF motifs (e.g., RUNX, TBX/EOMES) 37–40(Fig. 17E).
To quantify chromatin remodeling activities across the different phenotypic populations,
we performed differential chromatin accessibility analysis between Tprog, Tfh and Th1 effector
cells (Fig. 17F). Comparison of C7a and C6a Tprog cells identified 1,988 and 5,797
differentially accessible OCRs, while a comparison of C4a (Tfh) and C6a (Tprog) cells yielded
4,525 and 4,290 differential OCRs, respectively. Comparing C2a (Teff) to C6a (Tprog) cells
identified 5,482 and 2,616 differentially accessible OCRs, respectively. We performed motif
enrichment analyses at these specific OCRs and found that the Tprog populations exhibited
several motifs associated with NFAT and AP-1 binding in C6a, compared to C7a (Fig. 17G),
recapitulating the trajectory analysis. Enrichment of motifs for NFAT and AP-1 was lost during
the early transition from Tprog to Teff in addition to loss of TCF/LEF-related motifs (Fig. 17G),
which was consistent with loss of Tcf7 accessibility and expression (Fig. 17H; Fig. 16G). In
contrast, the most significantly enriched motifs were associated with RUNX activity, which have
been implicated in the commitment to the Th1 lineage

37,38

. During the transition from Tprog to

Tfh, we detected a similar reduction of accessibility to NFAT and AP-1 motifs, while several
motifs associated with the binding of basic helix-loop-helix (bHLH) proteins were enriched,
which have been shown to promote Tfh differentiation at the expense of Th1/Teff differentiation
35,41

.
Altogether, these results suggest that activated CD4 T cells adopt two distinct states of

TCF-1+ progenitor phenotypes: resting Tcmp-like (C2r/C7a) and activated memory (C3r/C6a)
states. Resting memory-like cells are mobilized to terminal differentiation by transient TCR
signaling, initially without polarization towards either lineage, and the specification of each
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terminal cell type is likely initiated after cells complete the transition to C6a through the
activation of lineage-specific TF binding motifs. These two-step processes may be distinct from
the initial differentiation towards either lineage as an immediate consequence of T cell activation
during the initial priming of naive T cells.

TCF-1+ BCL6lo/– cells exhibit superior proliferative capacity and give rise to both TCF-1– Teff
and TCF-1+ BCL6hi Tfh following adoptive transfer
To demonstrate the progenitor function of the TCF-1+ BCL6lo/– cells in vivo, we
compared repopulation and differentiation capacities of the three major subsets of PD-1+ CD4 T
cells isolated from LCMV-c13 infected mice. Each population was adoptively transferred into
congenic B6-CD45.1 mice, which were either subsequently infected with LCMV-c13, or
infection-matched at the time of transfer (Figs. 18 and 19). We used Ly-108 and CXCR5 as
surrogate surface markers for the expression of TCF-1 and BCL6 (Fig. 13G). Ly-108+ CXCR5–
(enriched for TCF-1+ BCL6lo/– cells), Ly-108+ CXCR5+ (enriched for TCF-1+ BCL6hi cells), and
Ly-108– CXCR5– (enriched for TCF-1– BCL6– cells) PD-1+ CD4 T cells were harvested as donor
cells from B6 mice that had been infected with LCMV-c13 for 21-24 days (Fig. 19A).
Following transfer to naive host mice and a subsequent challenge with LCMV-c13
infection (Fig. 19B), the donor-derived Ly-108+ CXCR5– cells expanded at a significantly higher
magnitude compared to the two other populations of donor cells (Fig. 19C, D). They repopulated
all three major populations of the PD-1+ CD4 T cell pool at similar ratios compared to those of
endogenous CD4 T cells (Fig. 19C, middle, and D), indicating their progenitor function. In
contrast, Ly-108– CXCR5– Teff cells remained predominantly as TCF-1– BCL6– cells and
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generated few TCF-1+ CD4 T cells with low overall proliferation (Fig. 19C, left, and D), an
indication of their terminal differentiation. Ly-108+ CXCR5hi Tfh cells expanded the least among
the three donor populations and gave rise to a higher frequency of TCF-1+ BCL6+ cells compared
to the other populations (Fig. 19C, right, and D). We detected TCF-1+ BCL6– and TCF-1– CD4
T cells in the mice that had received donor Tfh cells; however, the absolute numbers of these
cells were much lower than those derived from donor Teff or memory-like cells (Fig. 19D).
To more stringently test the ability of cells in each CD4 subset to proliferate and
differentiate, we performed transfers to infection-matched recipient mice (Fig. 18A-C). Spleens
from recipient mice were analyzed 15 days after transfer (36 dpi). Similar to the transfer to naive
host mice followed by rechallenge, total and Tet+ Ly-108+ CXCR5– PD-1+ cells demonstrated
the highest proliferation capacity with more than 10-fold expansion compared to Teff and Tfh
donor cells (Fig. 18B-E). They gave rise to all three populations at a ratio similar to endogenous
CD4 T cells, further demonstrating their lineage plasticity and self-maintenance. Since the
numbers of donor-derived cells 24 hour after transfer were comparable between Ly-108+
CXCR5– cells and Ly-108– Teff cells (Fig. 19E-G), we concluded that Teff cells are short-lived
with limited expansion capacity. In contrast, the engraftment of Tfh cells was substantially lower
compared to the other two populations (Fig. 19E-G), suggesting their impaired migration
possibly due to CXCR5 blockade as a result of cell sorting. While we detected small numbers of
TCF-1+ BCL6lo/– cells in recipients of Teff or Tfh cells, it is likely that the observed phenotypic
changes were caused by infrequent, contaminating memory-like cells during purification (Fig.
18E, F).
Together, the results from these adoptive transfer experiments demonstrated that the Ly108+ CXCR5– activated CD4 T cells retain high proliferative capacity and plasticity to
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differentiate into both TCF-1– Teff and TCF-1+ Tfh cells. These results suggest that they act as
progenitor cells to maintain the pool of differentiated Teff and Tfh cells.

TCF-1+ BCL6lo/– PD-1+ CD4 cells are progenitors that maintain TCF-1– effector cells in vivo
Our results thus far have shown that in the presence of chronic antigen, CD4 T cells
preferentially adopt the TCF-1+ BCL6lo/– phenotype after a wave of binary differentiation from
naive CD4 T cells into Teff and Tfh cells. TCF-1+ BCL6lo/– cells can give rise to TCF-1– Teff
cells following adoptive transfer and thus can function as progenitors for antigen-specific CD4 T
cells. To determine whether they are required for sustained CD4 Teff response, we conditionally
deleted Bcl6 in a CD4 T cell-specific manner. To achieve this, we generated a novel cre
transgenic driver that facilitates deletion of a loxP-flanked gene in CD4 T cells - with minimal
impact on CD8 T cells - by knocking-in cre into the Cd40lg locus on the X chromosome (Fig.
20A). This cre driver deleted a loxP-flanked transcriptional stop cassette in the Rosa26-stop-YFP
allele in virtually all CD4+ T cells, whereas its activity in CD8 T cells was substantially lower in
naive, Arm- and c13-infected mice (Fig. 20B-G). YFP+ cells were barely detectable in B cells,
myeloid cells, and NK cells (Fig. 20C, E). GC B cells were formed comparably in Cd40lg-cre
male mice compared to control mice (Fig. 20H). Comparable contribution of YFP+ and YFP–
CD4 T cells to Tfh cells in female Cd40lg-cre Rosa26-stop-YFP mice further indicates that cre
knock-in to the 3’ UTR preserved the function of the Cd40lg gene (Fig. 20I).
Using this animal model, we investigated the role of Bcl6 in the maintenance of longterm antigen-specific CD4 T cell response. On 8 dpi with LCMV-c13 infection, the number of
Tet+ cells was comparable in Cd40lg-cre Bcl6F/F compared to control Cd40lg-cre Bcl6+/+ mice
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(Fig. 21A, B). In Tet+ CD4 T cells, TCF-1+ cells were practically absent in Cd40lg-cre Bcl6F/F
mice with the number of TCF-1– CXCR6+ Teff cells remaining intact (Fig. 21C, D). This result
indicates that the deletion of Bcl6 was complete and that the development of both TCF-1+
BCL6hi Tfh and TCF-1+ BCL6lo/– cells requires Bcl6. In LCMV-Arm infected mice, Bcl6
deletion caused not only a loss of Tfh cells as defined by CXCR5+ PD1+ CD4 T cells or Tet+
TCF-1+ BCL6hi cells, but also a loss of TCF-1+ BCL6lo/– cells, which contains CCR7+ Tcmp cells
(Fig. 22A, B) that express low levels of BCL6 13. The CD4 Teff cells in c13-infected Cd40lg-cre
Bcl6F/F and control mice expressed comparable levels of the inhibitory receptor TIM3, indicating
they are qualitatively similar (Fig. 22C). Although the number of Teff cells was comparable
between Cd40lg-cre Bcl6F/F and control mice on 8 dpi, Tet+ cells were reduced more than 10-fold
by 15 dpi in Cd40lg-cre Bcl6F/F mice (Fig. 21C, D), indicating that the initially generated BCL6independent Teff cells derived from naive CD4 T cells are short-lived and that Bcl6 and BCL6dependent generation of TCF-1+ CD4 T cells are essential for the maintenance of BCL6– TCF-1–
Teff cells.
The TF Blimp1 plays antagonistic roles to BCL6 in the differentiation of Tfh versus Teff
CD4 T cells, memory versus effector CD8 T cells, and memory B versus plasma cells 9,34,42–47. In
the absence of Blimp1 in Cd40lg-cre Prdm1F/F mice, expansion of Tet+ CD4 T cells was
increased by 3-fold compared to control mice on 8 dpi with c13 (Fig. 22D, E). In addition to the
greater expansion, the vast majority of Tet+ CD4 T cells in Cd40lg-cre Prdm1F/F mice were TCF1+. Thus, Blimp1 not only regulates the expansion of antigen-specific CD4 T cells, but also
promotes the differentiation of TCF-1+ into TCF-1– CD4 T cells.
To determine whether TCF-1+ BCL6hi or Ly-108+ CXCR5+ Tfh cells are necessary for
the development of TCF-1+ BCL6lo/– cells or the maintenance of TCF-1– Teff cells, we analyzed
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MuMT mice lacking TCF-1+ BCL6hi Tfh cells. Although total Tet+ cells were mildly diminished
on 21 dpi, the frequency of cells in the TCF-1+ BCL6lo/– compartment was comparable to control
WT mice despite the total loss of TCF-1+ BCL6hi cells (Fig. 21E, F). These results indicate that
BCL6hi CXCR5hi cells are dispensable for the maintenance of antigen-specific CD4 T cells.
Furthermore, to determine whether Ly-108+ CXCR5– Tprog cells are sufficient to support
CD4-dependent immune response, we adoptively transferred distinct subsets of PD-1+ CD4 T
cells to infection-matched Cd40lg-cre Bcl6F/F mice on 21 dpi, in which host-derived LCMVspecific CD4 T cells were severely reduced (Fig. 21G-I). Four weeks after the transfer, the
numbers of GL7+ Fas+ B cells, enriched for GC B cells, were increased by 10-fold in recipients
of Ly-108+ CXCR5– donor CD4 T cells compared to those of either of the two other subsets,
indicating that transferred Tprog cells are sufficient to provide help to B cells. Taken together,
our results establish Bcl6 as a critical regulator of the differentiation of TCF-1+ BCL6lo/– Tprog
cells, which are indispensable for long-term, antigen specific CD4 T cell responses during
chronic viral infection.
Finally, to gain insights into the contribution of Tprog or Tfh CD4 T cells to the
maintenance of IL-21-dependent CX3CR1+ exhausted CD8 T cells

48,49

, we examined LCMV-

gp33-specific CD8 T cells in LCMV-c13-infected MuMT mice, lacking BCL6+ Tfh, and
Cd40lg-cre Bcl6F/F, in which antigen-specific CD4 T cells are severely reduced in the chronic
phase of LCMV-c13 infection. Although CD4 T cell depletion prior to infection almost
completely depletes the CX3CR1+ population of exhausted CD8 T cells, frequencies of
CX3CR1+ TCF-1– cells in gp33-specific CD8 T cells were only mildly reduced in both MuMT
and Cd40lg-cre Bcl6F/F mice (Fig. 23). Although the observed reduction confirms that antigenspecific CD4 T cells, or more specifically BCL6+ Tfh cells, play roles in the maintenance of
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CX3CR1+ exhausted CD8 T cells, these results suggest the presence of alternative sources of IL21 that are dependent on CD4 T cells specifically in early phases of infection.

Tumor antigen-specific CD4 T cells differentiate predominantly into TCF-1+ BCL6lo/– cells in
tumor-draining lymph nodes
Our results using viral infection models raise the question of whether a similar progenitor
population might support sustained antigen-specific CD4 responses during anti-tumor immune
responses. In order to examine CD4 T cell differentiation in anti-tumor immunity and determine
if it shows similarities to chronic LCMV infection, we examined the differentiation and
proliferation of OT-II CD4 T cells expressing an I-Ab-restricted OVA-specific TCR in response
to the subcutaneously transplanted ovalbumin (OVA) expressing 1956 sarcoma cell line 50. We
adoptively transferred CFSE-labeled, CD45.1/2 OT-II CD4 T cells one day prior to tumor
inoculation and tracked their proliferation by CFSE dilution and differentiation by staining for
TCF-1 and BCL6 in the tumor and tdLNs (Fig. 24A).
In tdLNs, OT-II CD4 T cells differentiated into all three populations defined by the
expression of TCF-1 and BCL6 (Fig. 24B, C). As we observed in LCMV-c13 infected mice, the
frequency of the TCF-1+ BCL6lo/– cells was the highest among expanded OT-II cells. Although
TCF-1– Teff, BCL6+ Tfh and the majority of TCF-1+ BCL6lo/– cells fully diluted CFSE over
several days, approximately 10% of TCF-1+ BCL6lo/– cells underwent limited rounds of division
and expressed higher levels of BCL6 compared to fully divided TCF-1+ cells (Fig. 24D-F).
Thus, the tumor-reacting TCF-1+ BCL6lo/– cells were heterogeneous, ranging from BCL6int/hi PD1lo dormant cells to extensively divided BCL6lo/– PD-1+ cells, which resembled Tprog found in
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LCMV-infected mice. In contrast to cells in tdLNs, OT-II cells isolated from the tumors were
predominantly TCF-1– CXCR6+ Teff cells (Fig. 24B, C). Since a small fraction of extensively
divided OT-II CD4 T cells in tdLN upregulated CXCR6 before downregulating TCF-1
expression (Fig. 24G), tumor-reactive CD4 T cells likely initiate their Teff differentiation during
the TCF-1+ state prior to migration to the tumor microenvironment. These results suggest that in
the setting of chronic antigen stimulation, rather than binary differentiation to TCF-1– BCL6– or
TCF-1+ BCL6+ populations, CD4 T cells preferentially differentiate into TCF-1+ BCL6lo/– cells,
which may serve as progenitors and continuously generate fully differentiated Teff and Tfh cells
as they continue to recognize antigen. These results also suggest that such continued
differentiation mainly takes place in tdLNs rather than in tumors, possibly because only the
tdLNs contain the appropriate microenvironment for TCF-1+ BCL6lo/– cells to retain a partially
differentiated phenotype.

3.4 Discussion
Using a combination of single-cell genomics and population-based experiments in the
chronic LCMV-c13 model, we demonstrate that antigen-specific CD4 T cells differentiate into
TCF-1+ BCL6lo/– PD-1+ CD4 Tprog cells that serve as progenitor cells and give rise to Teff and
Tfh cells in response to persistent antigen. During an acute infection or in response to
vaccination, significant proportions of Teff and Tfh cells are derived directly from naive CD4 T
cells

4,6

. In contrast, CD4 T cell response to chronic antigen is more complicated and requires

progenitor cells that can support long-term Teff responses as the initial Teff cells decay. This
process is illustrated in our Cd40lg-cre Bcl6F/F model, where the initial Teff cell expansion from
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naive cells was intact, but Teff cells fail to persist due to a lack of Tprog cells that generate new
Teff cells. Thus, the developmental pathway of CD4 Teff cells is shifted from BCL6independent to -dependent as antigen persists.
The CD4 Tprog cells identified in this study exhibit similarities to CD4 Tcm, Tcmp, and
pre-Tfh cells that also express Tcf7, Slamf6, and Bcl2, which allows for their long-term survival
in contrast to differentiated Teff and Tfh cells 1,6,14. Shortly after activation, ranging from several
hours to a few days, CD4 T cells diverge into IL2Ra+ Blimp1+ Teff cells and IL2Ra– BCL6+
cells in a B cell-independent manner 6,7. These IL2Ra– BCL6+ cells contain Tcmp and pre-Tfh 11.
This binary fate choice between Teff and Tfh is stable, since differentiation of adoptively
transferred IL2Ra– BCL6+cells is substantially biased towards Tfh, and the depletion of these
early IL2Ra– BCL6+ cells leads to a significant reduction of Tfh cells 4,11. In the contexts of acute
infection or immunization with non-replicating antigen, both antigen levels and inflammation
wane by the time pre-Tfh or Tcmp cells develop. In contrast, following LCMV-c13 infection,
antigen levels remain high for the first several days, rendering TCF-1+ PD-1+ CD4 T cells that
might otherwise become pre-Tfh or Tcmp exposed to continued signals through TCR and other
receptors. Such continued stimulation may result not only in changes in surface marker
expression, such as increased PD-1 and reduced CCR7 and CXCR5 compared to Tcmp

14

, but

also epigenetic changes that preserve Teff differentiation, although the newly defined Tprog
population is heterogeneous and may contain or overlap with committed pre-Tfh with a similar
surface phenotype.
Our single-cell analysis revealed two states of cells in the progenitor pool with distinct
activation signatures. The transition between the two states is associated with NFAT- and AP-1target gene activation; increased chromatin accessibility of these TF binding motifs was the
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dominant change between the two states. Trajectories between the resting progenitor state to Tfh
or Teff using both transcriptomic and epigenetic analyses suggest that the specification to either
lineage occurs independently of the initial transition from the resting to activated states.
Activation of E-protein targets, which may be mediated by E2A and ASCL2 35,41, in progenitorTfh trajectory and activation of RUNX targets for the Teff trajectory

37,38

were detected as CD4

Tprog cells acquire transient NFAT and AP-1 activation. Although a stringent validation may
require fate tracing at the single cell level, this conclusion is also supported by the substantially
overlapping TCR clonality among resting and activated Tprog, Tfh and Teff populations, while
Teff and Tfh are derived from distinct clones in the context of acute infection

51

. The activated

Tprog cells may overlap with previously described, BCL6-dependent PD-1+ CD4 T cells that
develop during M. tuberculosis infection 52.
Finally, our study highlights the similarities between CD4 Tprog and CD8 TPEX cells.
Both cell types develop in the presence of persistent antigen, express a shared transcriptional
program, including Tcf7, Slamf6, and Pdcd1, and continue generating differentiated effectors
while they self-renew. Although these cell types resemble CD4 Tcmp and CD8 MPEC,
respectively, they have unique gene expression and epigenetic signatures, such as those
associated with activation. In addition, we observed the emergence of PD-1+ CD4 T cells in
tumor-bearing mice, which phenocopy progenitor CD4 T cells in response to LCMV infection.
Many studies have demonstrated the importance of CD8 TPEX in enabling durable anti-tumor
immunity and the immune response to ICB therapies. CD8 TPEX cells are found in tumors and
extratumoral tissues, such as lymph nodes. In mouse tumor transplantation models, it has been
demonstrated that intratumoral CD8 TPEX cells are sufficient to promote anti-tumor immunity
in response to vaccine or ICB
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. In our tumor transplantation experiments, we found tumor82

reactive TCF-1+ PD-1+ CD4 T cells exclusively in the tdLNs while almost all antigen-specific
CD4 T cells in the tumor were differentiated TCF-1– Teff cells. In the LNs, a small fraction of
tumor-reactive TCF-1+ CD4 T cells initiate Teff differentiation as indicated by CXCR6
upregulation. CD4 T cell-dependent anti-tumor immunity is dependent on expression of BCL6 in
tumor-specific CD4 T cells, and enhanced by the presence of cognate B cells 54. The abundance
of non-Teff CD4 T cells suggests that such interaction between CD4 T and B cells may occur in
tdLNs, and in turn promote anti-tumor immunity in multiple mechanisms, including promoting
CD4 Teff differentiation and establishing an IL-21-rich environment.
During the revision of our manuscript, an independent study demonstrated the presence
of a CXCR5– CXCR6– memory-like CD4 T cell subset during chronic LCMV infection 55. This
study shows that Tfh cells derived from the memory-like cells are an essential source of IL-21 to
sustain CX3CR1+ exhausted CD8 T cells. It is likely that the described memory-like CD4 T cell
population overlaps with Tprog cells defined in the current work. However, it also remains to be
determined whether CXCR5+ Tfh cells are the predominant source of IL-21, given that both
MuMT and Cd40lg-cre Bcl6F/F mice largely maintain CX3CR1+ exhausted CD8 T cells despite a
specific lack of Tfh and a substantial loss of total antigen-specific CD4 T cells, respectively.
In summary, our analysis decoded the heterogeneity of CD4 T cells that respond to
persistent antigen in the context of antiviral and anti-tumor immunity and highlighted a
population of TCF-1+ BCL6lo/– PD-1+ CD4 T cells as progenitor cells that support the continued
generation of differentiated effectors and helper CD4 T cells. Progenitor CD4 T cells go through
a transitory state in which they retain an unbiased epigenetic signature towards either terminal
fate, and subsequently resolve the bipotential states, which is distinct from the binary
differentiation of naive CD4 T cells into Teff and Tfh early in an immune response. Our results
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reveal the population dynamics and differentiation hierarchy of CD4 T cells for their sustained
responses to persistent antigen.

3.5 Materials and Methods
Mice and infection
Male C57BL/6N (B6) and B6-CD45.1 mice were purchased from Charles River Laboratories
and JAX. Prdm1-EYFP, Bcl6-flox mice were obtained from the Jackson Laboratory. Cd40lg-cre
mice were generated by knocking in a mammalian codon optimized cre coding sequence
following an internal ribosomal entry sequence (IRES) into 3’ UTR of the Cd40lg locus by
homologous recombination in JM8.N4 embryonic stem cells. After germline transmission, the
FRT-flanked selection cassette was removed by crossing to Actb-Flpe transgenic mice (JAX).
Because the Cd40lg locus is on X-chromosome, all female mice used in the Bcl6 deletion
experiments were homozygous for cre knock-in. All mice were housed in a specific pathogenfree facility at Washington University in St. Louis and were used for infection at 8–12 wk of age,
unless stated otherwise. LCMV infection was performed essentially as described
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. All

experiments were performed according to a protocol approved by Washington University’s
Institutional Animal Care and Use Committee.

scRNA-seq and TCR-seq sample and library generation
Single-cell RNA-seq libraries were prepared using the 10X Chromium Next Gem Single Cell
V(D)J Reagent Kit (v1.1 Chemistry), according to the manufacturer’s instructions. Briefly,
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FACS sorted cells were washed once with PBS + 0.04% BSA and resuspended in PBS
containing 0.04% BSA. Following reverse transcription and cell barcoding in droplets, emulsions
were broken, and cDNA purified using Dynabeads MyOne SILANE followed by PCR
amplification (98°C for 45 sec; 14 cycles of 98°C for 20 sec, 67°C for 30 sec, 72°C for 1 min;
72°C for 1 min). Amplified cDNA was then used for both 5′ gene expression library construction
and TCR enrichment. For gene expression library construction, 50 ng of amplified cDNA was
used for fragmentation, following by and end-repair, double-sided size selection with SPRIselect
beads, PCR amplification with sample indexing primers (98°C for 45 sec; 14 cycles of 98°C for
20 sec, 54°C for 30 sec, 72°C for 20 sec; 72°C for 1 min), and double-sided size selection with
SPRIselect beads. For TCR library construction, TCR transcripts were enriched from 2 μl of
amplified cDNA by PCR (primer sets 1 and 2: 98 °C for 45 s; 10 cycles of 98 °C for 20 s, 67 °C
for 30 s, 72 °C for 1 min; 72 °C for 1 min). Following TCR enrichment, 5 - 50 ng of enriched
PCR product was fragmented and end-repaired, size-selected with SPRIselect beads, PCRamplified with sample-indexing primers (98 °C for 45 s; 9 cycles of 98 °C for 20 s, 54 °C for
30 s, 72 °C for 20 s; 72 °C for 1 min), and size-selected with SPRIselect beads. scRNA/TCR-seq
libraries were quantified using a Qubit dsDNA HS Assay kit (Invitrogen) and a HighSensitivity
DNA chip run on a Bioanalyzer 2100 system (Agilent). Sequencing was performed on NovaSeq
S4 (Illumina) with paired-end reads (2 x 150 cycles).

scRNA-seq and TCR-seq library processing
Reads from 10x scRNA expression libraries were aligned to mouse genome assembly GRCm38
(mm10) and quantified using cellranger count (10x Genomics, version 3.1.0). The filtered
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feature-barcode matrices containing only cellular barcodes were used for further analysis. Single
cell gene expression matrices were imported into R (version 3.6.1) and analyzed using Seurat
(version 3.1.1)57. Cells for which the number of genes captured fell within two standard
deviations of the mean of all cells in the library were kept. Additionally, cells with
mitochondrial RNA content percentages above the 95th-percentile

were excluded from

subsequent analyses.
Single cell TCR reads were aligned to mouse genome assembly GRCm38 (mm10) and
assembled into reconstructed TCR consensus sequences using cellranger vdj (10x Genomics,
version 3.1.0). Only productive TCRα and TCRβ sequences were considered for further analysis.
Overall, TCR sequences were annotated for 80,785 cells that passed RNA quality filtering, with
paired TCRαβ sequences detected for 71,818 cells (89.0%). Only cells with conventional paired
TCR chain combinations αβ or ααβ were kept for downstream clonotype analyses. Cells sharing
the same CDR3αβ amino acid sequences were defined as belonging to the same TCR clone.

scRNA-seq data integration and clustering
scRNA-seq libraries of I-Ab-LCMV-gp66 tetramer-sorted CD4 T cell populations from LCMVArm and LCMV-c13 at 8 dpi and 21 dpi were normalized individually while regressing out cell
cycle score. Cells passing quality filtering (80,785 cells) from all 19 samples (Fig. 11B-C) were
then integrated by identifying anchors between datasets using 30 reciprocal PCA dimensions.
TCR genes were excluded from the selection of integration anchors to prevent TCR chain driven
biases. Dimensionality reduction of the integrated matrix was performed using Uniform
Manifold Approximation and Projection (UMAP) with the first 15 principal components.
86

Phenotypic clusters were defined by constructing a k-nearest neighbors graph and identifying
groups of cells using the Louvain algorithm with resolution of 0.5.

CD8 gene signature scoring
To compare the CD4 T cell populations in LCMV infection identified by scRNA-seq to
previously described CD8 T cell populations, we computed gene signature scores for each cell
with Seurat’s AddModuleScore() function

57

using gene signatures of CD8 T cell subsets in

LCMV-c13 infection from Daniel et al., 2021

31

. Mitochondrial, TCR, and BCR genes were

removed from all gene sets in order to prevent biases due to library quality or TCR clonal
composition. Scores were then averaged per CD4 cluster to generate a mean composite signature
score for each CD4 population.

Trajectory inference
To perform trajectory analysis of the CD4 T cell response in LCMV-c13 infection,
dimensionality reduction of I-Ab-LCMV-gp66 Tet+ cells on 8 dpi (2 samples) and 21 dpi (4
samples) was performed using UMAP as described above after excluding cells belonging to the
Treg clusters C8-10r and other infrequent populations (C12-15r). Pseudotime analysis was then
performed with Monocle 3
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by learning a principal graph for the data and ordering cells along

the graph using the cells in the naive phenotype cluster to select a root node.

scATAC-seq sample and library generation
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Single cell ATAC-seq dataset is obtained from two biological replicates. Experiments were
performed on the 10x Chromium platform as described previously32. Briefly, following sorting,
cells were subjected to nuclei isolation according to the manufacturer's recommendation. After
tagmentation, nuclei were processed for generating scATAC-seq libraries and loaded to the 10x
Chromium controller. For GEM incubation the standard thermocycler conditions were used and
library construction was done as described by 10x Genomics for scATAC-seq. Libraries were
quantified using a Qubit dsDNA HS Assay kit (Invitrogen) and a HighSensitivity DNA chip run
on a Bioanalyzer 2100 system (Agilent). Sequencing was performed on NovaSeq S4 (Illumina)
with paired-end reads (2 x 150 cycles), and demultiplexed using CellRanger-ATAC v1.2.

scATAC-seq analysis
scATAC-seq datasets were processed as described previously
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. Briefly, reads were filtered,

trimmed, and aligned to the mm10 reference genome using the 10x cellranger atac-count
pipeline. Fragment files were loaded into ArchR for additional processing and analysis. Doublets
were identified and removed using ArchR’s default doublet simulation and calling procedures.
Barcodes were removed that had an enrichment of Tn5 insertions in transcription start sites (TSS
enrichment) less than 4 or less than 1000 fragments. Tiles and GeneScores matrices were
computed by summing Tn5 insertions in predefined genomic windows. After clustering the cells,
peaks were called by macs2
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on pseudoreplicates sampled from each cluster to obtain a

reproducible peak set retaining cell type specific peaks. scATAC-seq and scRNA-seq datasets
were integrated using the ArchR addGeneIntegrationMatrix() function, which directly aligns
cells from scATAC-seq with cells from scRNA-seq by comparing the scATAC-seq gene score
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matrix with the scRNA-seq gene expression matrix. For each cell in the scATAC-seq data, this
integration process finds the cell in the scRNA-seq data that looks most similar and assigns the
gene expression data from that scRNA-seq cell to the scATAC-seq cell. Dynamics of scRNA-seq
expression data can then be computed using this paired cell matrix. TF motif deviations were
computed using chromVar 61. Imputation was performed using Magic 62.

Cell preparation, cell staining, and flow cytometry
Single-cell suspensions of splenocytes were prepared by manual disruption with frosted glass
slides. Bone marrow cells were dissociated from the femur with mortar and pestle. Liver cells
were prepared by manual disruption with frosted glass slides followed by gradient centrifugation
with 40% Percoll. Absolute live cell counts were determined by trypan blue exclusion using ViCELL (Beckman Coulter). PE- or APC-labeled I-Ab-LCMV-gp66 tetramer reagents were
obtained from the NIH Tetramer Core at Emory and PE- or APC-labeled H2-Db-LCMV-gp33
tetramer reagents were obtained from MBL (TB-M512-1). Total splenocytes were stained with
MHC-tetramers at room temperature for 60 min. For analysis of T cells in the liver and lung,
circulating T cells were excluded by staining for biotinylated anti-CD3e that was intravenously
injected (3 ug) 3 minutes before euthanasia. For intracellular cytokine staining, total splenocytes were
cultured in RPMI-1640 supplemented with 10% FBS in the presence of 1 ug/ml of LCMV-gp61-80 peptide
(GenScript Biotech) and 5 ug/ml of Brefeldin A (BioLegend) for 4 h before staining. Cells for intracellular
staining were staining for surface proteins and then labeled with LIVE/DEAD Aqua (Thermo Fisher Scientific)
before fixation and intracellular staining using the Foxp3 staining kit (eBioscience) according to the

manufacturer’s instructions.
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The following antibodies were purchased from BioLegend, unless otherwise indicated:
Alexa Fluor (AF)-conjugated donkey polyclonal anti-rabbit IgG (Thermo Fisher Scientific,
catalog no. R37118); AF647–conjugated goat polyclonal anti-rabbit IgG (Cell Signaling, catalog
no. 4414S); AF700-conjugated anti-CD44 (IM7); APC-conjugated anti-PD-1 (29F.1A12); APCCy7-conjugated anti-CD8a (53-6.7, BD Biosciences); BV421- or BV711- conjugated antiCXCR5 (L138D7); Biotinylated anti-CD3e (145-2C11); PE-conjugated anti-GL7 (GL7); PerCPCy5.5-conjugated anti-CD4 (GK1.5); BUV395-conjugated anti-CD4 (GK1.5, BD Biosciences);
PerCP-Cy5.5-conjugated anti-CD45.1 (A20), A700-conjugated anti-CD45.2 (A20); anti-Ki67
(B56); PE-Cy7-conjugated anti-PD-1 (29F.1A12), anti-CD95 (Fas)(Jo2); PE-Dazzle 594conjugated anti-B220 (RA3-6B2), anti-CXCR6 (SA051D1); BV605-conjugated anti-Ly-108
(13G3, BD Biosciences); BV650-conjugated anti-CD150 (SLAM)(TC15-12F12.2); FITCconjugated anti-CD69 (H1.2F3); BV605-conjugated anti-CX3CR1 (SA011F11); PE-Cy7conjugated anti-LAG3 (C9B7W); BV421- or APC- conjugated anti-Tim-3 (RMT3-23);
eFluor660-conjugated anti-TOX (TXRX10, Thermofisher); unconjugated anti-TCF-1 (Cell
Signaling Technology, C63D9), BV421-conjugated anti-BCL6 (K112-91); PE-conjugated antiIFN-g (XMG1.2); APC-conjugated anti-IL-2 (JES6-5H4, BD Pharmingen); and APC-conjugated
TNF (MP6-XT22). Stained samples were analyzed with BD FACS LSR Fortessa, X20, or
Symphony A3 or sorted on Aria II or III. Data were analyzed using FlowJo Software (FlowJo).

Adoptive Transfer
For transfer into naive mice, CD4 T cells from the spleen and peripheral lymph nodes of B6 mice
on 22-24 dpi with LCMV-c13 were harvested and enriched for CD4 T cells using a MojoSort
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Mouse CD4 T Cell Isolation Kit (BioLegend) prior to surface staining. 180,000 - 250, 000 Ly108– CXCR5–, Ly-108+ CXCR5–, or Ly-108+ CXCR5+ PD-1+ CD4 T cells were sorted and
intravenously transferred into naive CD45.1 congenic recipients, which were infected with
LCMV-c13 the next day. For infection-matched transfer, donor CD4 T cells from B6 mice on 21
dpi with LCMV-c13 were bead-enriched, surface stained and sorted as described above. 1-2
million Ly-108– CXCR5–, Ly-108+ CXCR5–, or Ly-108+ CXCR5+ PD-1+ CD4 T cells were
transferred into infection-matched CD45.1 congenic recipients. Splenocytes from the recipient
mice were analyzed at time points described in Figure legends.

Tumor transplantation experiment
500,000 CFSE-labeled CD45.1/2 OT-II cells were intravenously transferred into B6 mice, which
were subcutaneously inoculated with 1 million 1956-mOVA cells50 the next day. Tumor
infiltrating lymphocytes (TILs) and cells in the tdLN were harvested 8 to 9 days after
inoculation. LN cells were prepared by manual dissociation with frosted glass slides and TILs
were prepared by digestion with Collagenase B, D1, and DNaseI, followed by staining with
fluorescently labeled antibodies as described above.

Statistical analysis
The P values were calculated with an unpaired two-tailed Student’s t-test and by one-way
ANOVA for multigroup comparisons with the Tukey post hoc test using Prism 9 software
(GraphPad): *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
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Data availability
All single-cell sequencing data generated in this paper have been deposited in the Gene
Expression Omnibus (GEO) database under accession number GSE181474.
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Figure 11. Sorting and library quality metrics of scRNA/TCR-seq samples from splenic
CD4 T cells in LCMV-Arm and LCMV-c13.
(A) Sorting strategy of gp66-Tet+ and -Tet– scRNA/TCR-seq samples from LCMV-Arm and
LCMV-c13.
(B) Sequencing metrics of paired scRNA/TCR-seq libraries, including number of reads per cell
(top left), number of genes per cell (top right), percent mitochondrial read per cell (bottom left),
and TCRαβ chain capture efficiency (bottom right).
(C) UMAP of cells from each scRNA-seq replicate colored by phenotypic cluster.
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Figure 12. scRNA-seq and flow analysis reveals heterogeneity within antigen-specific CD4
T cells in chronic LCMV infections.
(A) UMAP of LCMV-Arm 8 and 21 dpi, LCMV-c13 8 and 21 dpi CD4 T splenocytes sorted for
gp66 Tet+ and Tet- populations. Cells are clustered by scRNA-seq gene expression profiles and
colored by phenotype (top). Density UMAP of CD4 T cells from each condition and tetramer-
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sorted population (bottom left). Proportion of cells from each condition in each phenotypic
cluster (bottom right).
(B) Expression of cluster-defining markers.
(C) Differential gene expression of cells in the resting memory cluster C2r compared to the
activated memory-like cluster C3r (left). Differential gene expression of gp66-Tet+ resting
memory C2r cells from LCMV-Arm 21 dpi compared to LCMV-c13 21 dpi (right).
(D-G) Expression of TCF-1, BCL6, CXCR5, Ly-108, and CD69 by gp66-specific splenic CD4 T
cells and expression of Fas and GL7 in B cells in the spleen from in LCMV-c13-infected B6
mice at indicated time points. Representative flow cytometry plots are shown with pooled data
for the frequencies of each PD-1+ CD4 T cell population from 2 experiments (n = 2-3 /
experiment) as mean±SD in (F). Unpaired t-test.
(H) Expression of indicated proteins or a Prdm1-YFP reporter in gp66 specific splenic CD4 T
cell subpopulations from LCMV-c13 infected B6 mice. Data are representative of 2 experiments
with n = 2-3 / experiment.
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Figure 13. Characterization of antigen-specific CD4 T cells in chronic LCMV infections.
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(A) Heatmap of the top 10 differentially expressed markers for each scRNA-seq cluster. Colors
represent normalized (z-scored) expression per gene among each cluster.
(B) Expression levels of select cluster markers and T cell subset defining genes within each
cluster.
(C) Differential gene expression of gp66-Tet+ resting memory C2r cells from LCMV-Arm d8
dpi compared to LCMV-c13 8 dpi.
(D) Expression levels of progenitor, memory, and activation-induced markers among gp66tetramer-sorted cells in the resting memory C2r cluster on 21 dpi in LCMV-Arm and LCMV-c13
infection.
(E) Frequencies of memory and memory-like clusters among gp66-tetramer-sorted samples on
21 dpi in LCMV-Arm and LCMV-c13 infection. Each dot indicates one replicate.
(F) Representative flow cytometry plots showing expression of PD-1 and Foxp3 in gp66-specific
splenic CD4 T cells in B6 mice infected with LCMV-c13 22 days before the analysis. Pooled
data from 2 experiments with 2-3 mice / experiment are shown with mean±SD. Statistical
analysis by one-way ANOVA.
(G) Representative flow plots showing expression of CXCR5, BCL6, Ly-108, and TCF-1 in
gp66 -specific splenic CD4 T cells in B6 mice infected with LCMV-c13 8 day or 22 days before
the analysis.
(H, I) Representative flow plots showing expression of BCL6 and TCF-1 in PD-1+ CD4 T cells
in B6 mice infected with LCMV-c13 15 day before the analysis (G). Pooled data are shown in
(H) with mean±SD. Statistics analysis with one-way ANOVA.
(J) IFN-g, IL-2 and TNF production of CD4 T cells in splenocytes harvested from B6 mice at 21
dpi and stimulated with gp61-77 peptide ex vivo. Cytokine production by the three CD4 T cell
populations is shown on the left, and quantification is shown on the right with data pooled from 2
experiments with 2-3 mice / experiment. Data is shown as mean±SD. Statistical analysis done by
one-way ANOVA.
(K) Heatmap of CD8 gene signature scores 31 for each CD4 cluster. Colors represent normalized
(z-scored) means per CD8 gene signature.
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Figure 14. Memory-like cells are enriched for common progenitors for both Tfh and Teff.
(A) UMAP trajectory graph of gp66-Tet+ CD4 T cells from LCMV-c13 infected B6 mice on 8
and 21 dpi colored by phenotypic clusters as in Fig. 12A. The Treg clusters and other infrequent
populations were excluded from the trajectory analysis for clarity.
(B) UMAP trajectory of gp66-Tet+ CD4 T cells from LCMV-c13 infected B6 mice on 8 and 21
dpi along the Tfh branch (top) or Teff branch (bottom). Cells are colored by pseudotime.
(C) Gene expression dynamics of activation and Tfh lineage markers along the Tfh pseudotime
trajectory.
(D) Gene expression dynamics of activation and Teff markers along the Teff pseudotime
trajectory.
(E) Phenotypic overlap of expanded (>1 cell) T cell clones among the resting memory, activated
memory-like, Tfh, and Teff clusters. Bars are colored by the category of clonal phenotypic
overlap.
(F) Phenotypic composition of the top 10 most highly expanded gp66-Tet+ clones from LCMVc13-infected B6 mice on 21 dpi.
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Figure 15. Clonal expansion of gp66 Tet+ T cells from LCMV-c13-21 dpi.
(A) UMAP of gp66-Tet+ CD4 T cells from LCMV-c13-infected B6 mice on 8 (top) and 21
(bottom) dpi colored by pseudotime.
(B) UMAP of LCMV-Arm and LCMV-c13 CD4 T splenocytes on 8 dpi and 21 dpi sorted for
gp66-Tet+ and Tet– populations, colored by clone size.
(C) Clonal expansion levels of TCR clones from gp66-Tet+ and Tet– splenic CD4 T cells on 8
and 21 dpi in LCMV-Arm and LCMV-c13 infection.
(D) Frequencies (top) and Gini indices (bottom) of TCR clones from gp66-Tet+ and Tet– splenic
CD4 T cells on 8 and 21 dpi in LCMV-Arm and LCMV-c13 infection.
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Figure 16. scATAC-seq identifies chromatin features of Tprog, Tfh and Teff populations.
(A) Sorting strategy of scATAC-seq and scRNA-seq samples used for the integrative analysis of
CD4+ PD-1+ T cells.
(B) UMAP of scATAC-seq biological replicates of PD-1+ CD4 T cells sorted on 21 dpi of
LCMV-cl13 infection.
(C) Quality control of scATAC-seq data. Fragment distribution of scATAC-seq libraries (left),
Normalized insertion profile at the transcription start site (TSS) of genes (middle). Density plot
of TSS read enrichment and unique fragments in single cells (right).
(D) Violin plot representation of gene scores for Cxcr5, Tcf7, Slamf6 and Tbx21.
(E) Heatmap of marker gene accessibility scores of the progenitor population.
(F) UMAP of gene score (accessibility) values for the indicated genes.
(G) Pseudotime analysis of the gene scores (accessibility) and gene integration scores (integrated
expression values) of the indicated genes.
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Figure 17. Chromatin accessibility analysis reveals heterogeneity and delineates the main
CD4 differentiation pathways during chronic viral infection.
(A) UMAP of scATAC-seq data of PD1+ CD4 T cells on 21 dpi of LCMV-cl13 infection.
(B) UMAP of gene score (accessibility) and gene integration matrix (expression) for Cxcr5,
Slamf6 and Tbx21.
(C) Heatmap visualization of marker gene accessibility scores across clusters represented by
gene score values.
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(D) Heatmap of marker peak scores of 5,227 cis-regulatory elements in scATAC-seq clusters
(left). Heatmap of enriched motifs in marker peaks of the specific clusters (right).
(E) UMAP projection of Tfh and Teff differentiation trajectory, respectively. Cells that are not
part of the trajectory are colored grey (top). Pseudotime heatmaps of motif deviation scores on
the two differentiation trajectories (bottom).
(F) Volcano plot visualization of the differential peak analysis between the indicated clusters
(FDR <= 0.1 and a Log2FC >= 0.5)
(G) Hockey plot representation of the enriched motifs under the cluster specific peak sets.
(H) Pseudotime analysis of the gene scores (accessibility) and gene integration scores (integrated
expression values) of the indicated genes.
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Figure 18. TCF-1+ BCL6lo/– PD-1+ CD4 T cells are capable of superior expansion and
differentiation into both Teff and Tfh following adoptive transfer.
(A) Experimental design of adoptive transfer of distinct populations of PD-1+ CD4 T cells from
LCMV-c13 infected mice to infection-matched recipient mice for the experiments shown in (B,
C) and (D, E). For the experiments shown in (B, C), 1 x 106 PD-1+ CD4 T cells were transferred.
For the experiments shown in (D, E), 1 to 2 x 106 PD-1+ CD4 T cells containing an estimated
amount of 4.5 x 104 Tet+ cells were transferred.
(B-E) Representative flow cytometry data showing frequencies of total donor-derived cells (B)
and Tet+ donor-derived cells (D) and their expression of TCF-1 and BCL6 15 days after transfer
are shown. Pooled data from 2 experiments with n = 2-4 / transfer group / experiment are shown
in (C, E) with mean±SD and statistical analysis by One-way ANOVA. Frequencies and total
numbers of donor-derived cells in (B, C) were normalized to 1 x 106 transferred donor cells, and
frequencies and total numbers of Tet+ donor-derived cells in (D, E) were normalized to 4.5 x 104
Tet+ transferred donor cells.
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Figure 19. Sorting strategy and “take” analysis of adoptive transfer experiments
(A) Sorting strategy of donor cells using PD-1, Ly-108 and CXCR5 for all experiments
performed in Fig. 18 and Fig. 19.
(B-D) Adoptive transfer of distinct populations of PD-1+ CD4 T cells from LCMV-c13 infected
mice to naive mice subjected to subsequent infection with LCMV-c13. (B) shows the
experimental design.1.8 - 2.5 x 105 PD-1+ cells were transferred. Representative flow cytometry
data showing frequencies of donor-derived cells and their expression of TCF-1 and BCL6 15
days after infecting the recipient mice with LCMV-c13 were shown in (C). Pooled data from 2
experiments with n = 3 / transfer group / experiment are shown in (D) with mean±SD with
statistical analysis with One-way ANOVA. Percentages and numbers of donor-derived cells
shown in (D) are normalized to a transferred amount of 1 x 105 cells.
(E-G) Measurement of donor cell engraftment following infection-matched adoptive transfer of
distinct populations of PD-1+ CD4 T cells. 1 x 106 PD-1+ cells were transferred. Experimental
design is shown in (E) where spleens of recipients were harvested one day after the transfer.
Representative flow cytometry data showing frequencies of donor-derived cells and their
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expression of Ly-108 and CXCR5 were shown in (F). Pooled data from 2 experiments with n =
2-3 / transfer group / experiment are shown in (G) with mean±SD with statistical analysis with
One-way ANOVA.

Figure 20. The generation of Cd40lg-cre knock-in mice and validation of cre activity.
(A) Targeted insertion of a codon-optimized cre (hCre) coding sequence followed by an internal
ribosomal entry sequence into the 3’ UTR of Cd40lg by homologous recombination in B6derived JM8 ES cells. After obtaining germline transmission of the targeted allele, the FRTflanked selection cassette was removed in vivo by crossing to Flpe transgenic mice.
(B-E) Expression of YFP in thymocyte (B), splenocyte (C), peripheral blood mononuclear cell
(D) and liver mononuclear cell (E) subpopulations from uninfected Cd40lg-cre Rosa26(loxPstop-loxP-YFP) mice. Data are shown with representative flow cytometry plots and mean±SD
from 3-8 mice.
(F, G) Expression of YFP in splenic CD4 and CD8 T cells (F) and expression of GL7 and Fas by
splenic B cells (G) in LCMV-Arm-infected Cd40lg-cre Rosa26(stop-YFP) mice. Data are shown
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with representative flow cytometry plots and mean±SD from 3 mice. P-values by t-test: % of
B220+ CD19+/spleen: P = 0.815, % of GL7+ Fas+/B220+ CD19+: P = 0.122.
(H) Expression of YFP in CD62L+ CD44– CD4 splenocytes and CXCR5+ PD1+ CD4 splenocytes
of female Cd40lgcre/+ Rosa26-stop-YFP mice 15 days post LCMV-Arm infection. Representative
flow plots and data pooled from 2 experiments with 3-4 mice / experiments are shown.
(I) Expression of YFP in PD-1+ splenic CD4 and CD8 T cells from LCMV-c13-infected Cd40lgcre Rosa26-stop-YFP mice on 21 dpi. Data is representative of 2 experiments with 3-4 mice /
experiments.
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Figure 21. The maintenance of TCF-1– Teff cells requires BCL6-dependent, B cellindependent, TCF-1+ BCL6lo/– PD-1+ memory-like CD4 T cells
(A-B) Representative flow cytometry plots showing expression of CD44 and gp66-specific TCR
in splenic CD4 T cells in Cd40lg-cre Bcl6F/F and control Cd40lg-cre mice infected with LCMVc13, analyzed on 8 dpi, 15 dpi or 28 dpi. Pooled data from 2 experiments with 2-3
mice/group/time point are shown with mean±SD. Unpaired t-test.
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(C-D) Expression of TCF-1, BCL6, Ly-108, CXCR5 and CXCR6 in gp66-specific splenic CD4
T cells from LCMV-c13-infected Cd40lg-cre Bcl6F/F and control Cd40lg-cre mice on 8 dpi. Data
pooled from two experiments with n = 2-4 per genotype are shown with mean±SD.
(E-F) Expression of TCF-1, BCL6 and CXCR6 in gp66-specific splenic CD4 T cells from
LCMV-c13-infected MuMT and age-matched B6 (WT) mice on 21 dpi. Data from two
experiments with n = 2-5 per genotype per experiment are shown with mean±SD.
(G-I) Adoptive transfer of distinct populations of PD-1+ CD4 T cells from LCMV-c13 infected
B6-CD45.1 mice to infection-matched Cd40lg-cre Bcl6F/F recipients (CD45.2).
Experimental design (G): adoptive transfer of 0.7 to 1 x 106 cells of distinct PD-1+ CD4 T cell
population from LCMV-c13 infected donor mice to infection-matched Cd40lg-cre Bcl6F/F
recipients. 27 days after transfer, frequencies of GL7+ Fas+ B cells in the spleen from recipient
mice were analyzed. Representative flow cytometry plots (H) and pooled data from 2
experiments (n = 2-4 / transfer group / experiment) are shown in (I) with mean±SD with
statistical analysis by One-way ANOVA.
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Figure 22. BCL6 and Blimp1 are essential for the differentiation of TCF-1+ and TCF-1–
antigen-specific CD4 T cells, respectively, during LCMV infection.
(A, B) Expression of PD-1, CXCR5, TCF-1, BCL6 and CCR7 in splenocytes from LCMV-Arminfected Cd40lg-cre or Cd40lg-cre Bcl6F/F mice on 8 dpi. Representative flow plots (A) and
pooled data from 2 experiments with n = 2-3 / genotype /experiment are shown with mean±SD in
(B).
(C, D) Expression of TCF-1 and TIM3 in PD-1+ CD8 T cells (C, top) and gp66-Tet+ CD4 T cells
(C, bottom) in the spleen of LCMV-c13-infected Cd40lg-cre or Cd40lg-cre Bcl6F/F mice on 8dpi.
Histogram overlays of TCF-1–-gated cells from each of the parental populations are shown (C,
right). Mean fluorescence intensity (MFI) of TIM3 from 2 experiments with n = 24/genotype/experiment is shown with mean±SD in (D).
(E, F) Expression of TCF-1 and BCL6 by gp66-Tet+ CD4 T cells in the spleen from LCMV-c13infected Cd40lg-cre or Cd40lg-cre Prdm1F/F mice on 8 dpi. Representative flow plots (E) and
pooled data from 2 experiments with n = 2-4 / genotype /experiment are shown in (F) with
mean±SD. Statistical differences were assessed by unpaired t-test.
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Figure 23. IL-21-dependent CX3CR1+ exhausted CD8 T cells in LCMV-c13-infected mice
are maintained in the absence of Bcl6 in CD4 T cells.
(A, B) Expression of PD-1, TCF-1 and CX3CR1 in LCMV-gp33-specific CD8 T cells in the
spleen from LCMV-c13-infected MuMT mice on 21 dpi. Representative flow cytometry plots
(A) and pooled data from 2 experiments with n = 2-3 / genotype /experiment are shown with
mean±SD. Unpaired t-test.
(C, D) Expression of PD-1, TCF-1 and CX3CR1 in LCMV-gp33-specific CD8 T cells in the
spleen from LCMV-c13-infected Cd40lg-cre Bcl6F/F mice on 21 dpi. Representative flow
cytometry plots (C) and pooled data from 2 experiments with n = 2-3 / genotype /experiment are
shown with mean±SD. Unpaired t-test
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Figure 24. Antigen-specific CD4 T cells differentiate into TCF-1+ PD-1+ cells following cell
division in tumor-draining lymph nodes, but not in the tumor microenvironments.
(A) Experiment design to examine CD4 T cell response to tumor antigen.
(B-C) Representative flow plots showing expression of TCF-1 and BCL6 by donor-derived OTII CD4 T cells harvested from tumor (TIL) and the tumor draining lymph node (tdLN). Data are
pooled from two experiments (n = 6 - 8 per experiment) and shown with mean±SD. (D-F) CFSE
dilution and expression of BCL6, TCF-1, CXCR6, PD-1 and CD44 of donor-derived OT-II cells.
The CFSE level of naive OT-II cells was determined by control recipient mice without tumor
transplantation sacrificed at the same time points. Left panels in (E) show only tdLN-derived
OT-II cells without overlay of TIL or naive cells. Pooled data are shown with mean±SD in (F)
with assessment of statistical differences by one-way ANOVA.
(G) Representative flow cytometry plots showing expression of CXCR6, TCF-1 and BCL6 by
donor-derived OT-II CD4 T cells harvested from tdLN and the tumor. Numbers shown are
mean±SD.
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Chapter 4: Discussion
In this work, we have sought to understand the mechanisms that maintain CD8 and CD4
T cell responses in the presence of persistent antigens, using the chronic strain of LCMV as the
main model. In Chapter 2, we focused on understanding the population dynamics of CD8 T cells,
where we identified and characterized a previously unknown exhausted CD8 subset marked by
the expression of CX3CR1. CX3CR1+ cells can be further divided into a TIM3– portion that
expresses low levels of TCF-1 and a TIM3+ portion that carry more effector functions. CX3CR1+
TIM3– cells give rise to CX3CR1+ TIM3+ cells, and together comprise a relatively stable
exhausted/effector CD8 subset that requires little input from the previously identified TCF1hi
progenitor exhausted (TPEX) subset. In Chapter 3, we turned our attention toward CD4 T cells
and discovered that a memory-like CD4 T cell population exists which serves as a bipotential
progenitor for both TFH and non-Tfh effector cells (Teff), thus enabling a durable CD4 T cell
response in the presence of persistent antigens. This progenitor CD4 population relies on the
transcription factor BCL-6 for formation. Our studies shed light on the heterogeneity of CD8 and
CD4 T cells during chronic viral infections and on the mechanism of how T cells maintain those
heterogeneity as the infection goes on, a challenge that T cells in acute infection or vaccination
models do not need to tackle.
The identification of CX3CR1+ CD8 population is significant as it challenges the idea
that exhausted cells are dysfunctional and the idea that the TPEX population constantly feeds
into the TCF1lo/– terminally differentiated CD8 T cell compartment. For the first point, although
CD8 T cell response in chronic LCMV infection, on the population level, exhibit less effector
functions compared to that in acute infections1-3, caution need to be taken regarding what the
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data means and to whether the CD8 T cell response in acute infection models should be deemed
as a “better” or more “normal” response . Previous data looked at the exhausted TCF1lo/–
4

population as a whole5, 6, and here we report that within the exhausted TCF1lo/– population there
are cells with higher effector functions, namely the CX3CR1+ TIM3+ cells. For the second point,
our data suggests that the previously identified TPEX cells likely feed into the more exhausted
CD8 T cells at a rate lower than previously thought. Although the TPEX cells are what responds
to the anti-PD-1 or anti-PDL1 blockade and give rise to more effector/exhausted cells, there is no
reliable data aside from our study to this day regarding the rate at which this mobilization
happens in vivo. Because TPEX cells express a high level of and are dependent on TCF-1, Tcf7
(which encodes for TCF-1) knockout (KO) models have been used as a model that specifically
lacks the TPEX population5, 7, 8, and phenotypes discovered using those models have been used
to infer the function of TPEX. However, TCF-1 is required for thymic development and is also
9

expressed by the CX3CR1+ TIM3– cells, albeit at a lower level, which draws into question to
what extent the Tcf7-KO phenotypes are solely due to a lack of TPEX. With our Cx3cr1creERT2/+
R26tdT fate-mapping mice, we showed evidence that the CX3CR1+ compartment is stable with
little loss of fate-mapped cells, which suggest minimal input from the TPEX cells within the
window of observation in our study. Therefore, our study contributes to our understanding of
CD8 T cell response in the presence of persistent antigens by providing a non-biased
characterization of the CD8 T cell heterogeneity and a careful study of their population dynamics
in vivo.
CD4 T cell plasticity is a well-known phenomenon and this study furthers our
understanding in this regard by the identification of a bipotential progenitor population in the
presence of persistent antigens that could differentiate into either Tfh or non-Tfh effector cells.
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Plasticity between Th17 and Th1 has been documented in various infection and autoimmunity
settings, where Th17 cells can give rise to cells with Th1 characteristics10, 11. It is unclear if the
Th17 and Th1 conversion can occur by direct trans-differentiation or de-differentiation of Th17
cells first followed by differentiation into Th1 cells. Results of our study are more in line with
the second possibility, although it is likely that CD4 T cells in different contexts utilize different
differentiation approaches to achieve plasticity depending on the epigenetic landscape of the
cells and the microenvironment that they are in.
Since its discovery as a transcription factor required for Tfh differentiation12, 13, BCL6
has been called the Tfh lineage-defining transcription factor. However, our study shows that
BCL6 functions beyond Tfh differentiation by promoting formation of memory-like progenitor
cells. Likely, BCL6 antagonizes BLIMP-1 early during CD4 T cell differentiation13-15, thus
preserving the stemness of the BCL6+ cells and their progenies. This is in line with previous
reports that BCL6 is required for CD4 central memory formation following acute bacterial or
viral infections16, 17, and might partially explain the perplexing Tfh memory phenotype that Tfh
memory cells are multipotent and upon rechallenge give rise to both Tfh and effector T (Th1)
cells, as BCL6 might also function in Tfh cells to preserve their stemness9, 18, 19. In this sense, our
work points to new functions of BCL6 and provides a unifying explanation for the multipotency
shown by Tfh memory cells, T central memory cells, and progenitor cells.
Although not a main focus, our work also provides some information on the mechanism
of CD4 help for CD8 T cell response in the presence of persistent antigens. CD4 depletion in the
beginning of the chronic LCMV infection has no impact on the formation of CX3CR1+ cells but
impairs their maintenance. By 21 days post infection, there are few CX3CR1+ CD8 T cells left.
Cd40lg-cre Bcl6F/F mice, on the other hand, have CD4 T cells for the first week of infection and
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maintain a largely intact CX3CR1+ CD8 T cell response by 21 days post infection. These two
lines of evidence suggest that it is the CD4 T cell response during the first week of infection that
is crucial for a maintenance of CX3CR1+ CD8 T cell response. In other words, a large part of the
CD4 T cell help to CD8 T cells likely occurs during the priming phase of the infection.
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